ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2010

¨

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from
to

Commission file number: 001-34207

Dynavax Technologies Corporation

(Exact name of registrant as specified in its charter)

Delaware

33-0728374

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

2929 Seventh Street, Suite 100

Berkeley, CA 94710-2753

(510) 848-5100

(Address, including Zip Code, and telephone number,
including area code, of the registrants principal executive offices)

Securities
registered pursuant to Section 12(b) of the Act:

Title of Each Class:

Name of Each Exchange on Which Registered:

Common Stock, $.001 Par Value

Preferred Shares Purchase Rights

The NASDAQ Stock Market LLC

Securities Registered Pursuant to Section 12(g) of the Act:

None

Indicate by
check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes
¨
No
x

Indicate by check mark if the registrant is not required to file reports pursuant
to Section 13 or Section 15(d) of the Act. Yes
¨
No
x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90
days. Yes
x
No
¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registration was required to submit and post such
files). Yes
¨
No
¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will
not be contained, to the best of the registrants knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form
10-K.
x

Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of
the Exchange Act. (Check one):

Large accelerated filer
¨

Accelerated filer
x

Non-accelerated filer
¨

Smaller reporting company
¨

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Act). Yes
¨
No
x

The aggregate market value of the voting and non-voting stock held by non-affiliates of the registrant, based upon the closing sale price
of the common stock on June 30, 2010 as reported on the NASDAQ Capital Market, was approximately $142,099,406. Shares of common stock held by each officer and director and by each person known to the Company who owns 5% or more of the
outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

As of March 8, 2011, the registrant had outstanding 115,689,769 shares of common stock.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Definitive Proxy Statement for the registrants 2011 Annual Meeting of Stockholders are incorporated by reference into Part III, Items 10-14 of this Form 10-K.

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934 which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking statements, including statements about our business strategy
and regulations, our future research and development and intellectual property position, our product development efforts, our ability to commercialize our product candidates, the timing of the introduction of our products, the effect of GAAP
accounting pronouncements, the potential for entry into collaborative arrangements, uncertainty regarding our future operating results and our profitability, anticipated sources of funds as well as our plans, objectives, expectations and intentions.
These statements appear throughout our document and can be identified by the use of forward-looking language such as may, will, should, expect, plan, anticipate,
believe, estimate, predict, future, intend, or certain or the negative of these terms or other variations or comparable terminology.

Actual results may vary materially from those in our forward-looking statements as a result of various factors that are identified in
Item 1ARisk Factors and Item 7Managements Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this document. No assurance can be given that the risk factors described in
this Annual Report on Form 10-K are all of the factors that could cause actual results to vary materially from the forward-looking statements. All forward-looking statements speak only as of the date of this Annual Report on Form 10-K. Readers
should not place undue reliance on these forward-looking statements and are cautioned that any such forward-looking statements are not guarantees of future performance. We assume no obligation to update any forward-looking statements.

This Annual Report on Form 10-K includes trademarks and registered trademarks of Dynavax Technologies Corporation.
Products or service names of other companies mentioned in this Annual Report on Form 10-K may be trademarks or registered trademarks of their respective owners.

Our pipeline of product candidates includes: HEPLISAV; clinical-stage programs for our
Universal Flu vaccine and hepatitis C and hepatitis B therapies; and preclinical programs partnered with GlaxoSmithKline (GSK) and AstraZeneca. We compete with pharmaceutical companies, biotechnology companies, academic institutions and
research organizations in developing therapies to prevent or treat infectious and inflammatory diseases. Our product candidates are based on the use of immunostimulatory and immunoregulatory sequences. We were incorporated in California in
August 1996 under the name Double Helix Corporation, and we changed our name to Dynavax Technologies Corporation in September 1996. We reincorporated in Delaware in 2001. Our principal offices are located at 2929 Seventh Street,
Suite 100, Berkeley, California 94710-2753. Our telephone number is (510) 848-5100.

Immunostimulatory Sequences
(ISS)

Our proprietary technology platform includes ISS, which are short DNA sequences that enhance the ability of the
immune system to fight disease. ISS activate the innate immune response by specifically targeting TLR9, which is found on a specialized subset of immune cells.

ISS work by changing or reprogramming the immune responses that cause disease rather than
just treating the symptoms of the disease. Since TLR9 is found only in a specialized subset of dendritic cells, ISS do not cause a generalized activation of the immune system and redirect the response of only those T cells involved in a given
disease. When linked to or combined with antigens, ISS help generate memory Th1 cells that can reprogram the immune system to induce long-lasting therapeutic effects.

We have developed a number of proprietary ISS compositions and formulations that make use of the different ways in which the innate immune system responds to ISS. Depending on the indication for which ISS
is being explored as a therapy, we use ISS in different ways.

ISS Linked to or Combined with Antigens

For prevention of infectious diseases, ISS can be linked to or combined with antigens to increase the visibility of the antigen and
stimulate an immune response that will attack and destroy infected or abnormal cells. This treatment induces a highly specific Th1 immune response and generates memory T cells for long-term protection. This treatment has the potential to be used
synergistically with other therapies.

ISS Alone

For treatment of viral and respiratory diseases, ISS can be used alone to modify the course of the disease by reprogramming the immune
system. ISS suppress the Th2 inflammatory response caused by any number of allergens to modify the underlying cause of inflammation as well as provide symptomatic relief.

Advanced ISS Technologies

For several programs, we use our advanced
proprietary knowledge to design modifications of the molecular structure of ISS to significantly increase their versatility and potency, allowing use of less ISS. These second-generation ISS stimulate specific immune responses, including potent
interferon-alpha induction.

Immunoregulatory Sequences (IRS)

Our proprietary technology platform includes IRS, which are short DNA sequences that specifically inhibit TLRs associated with autoimmune
and inflammatory diseases. TLRs are key receptors of the innate immune system that can induce strong inflammatory responses. In animal studies as well as in-vitro, our TLR inhibitors have demonstrated broad potential in multiple autoimmune diseases
models, such as lupus, inflammatory skin disorders, and rheumatoid arthritis.

Our lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to enhance protection more rapidly
with fewer doses than current licensed vaccines. Our global strategy is to develop HEPLISAV for adults who are at risk of hepatitis B infection, initially in populations that are less responsive to current licensed vaccines, including adults over 40
years of age, individuals with chronic kidney disease, diabetics and others.

HEPLISAV is being evaluated in Phase 3 trials that are directed toward fulfilling
licensure requirements in the United States, Canada and Europe. The ongoing large-scale Phase 3 lot-to-lot consistency and safety trial is expected to be completed in May 2011, after a 12-month follow-up of these subjects. Enrollment for the Phase 3
trial in chronic kidney disease patients was completed in January 2011. There have been four safety assessments made by an independent data safety monitoring board, all of which have recommended the trials continue without protocol modification. In
February 2011 following completion of the fourth planned safety assessment, the DSMB determined that no other formal meetings of the DSMB are required.

Clinical Results

Over 4,000 individuals have
been vaccinated with HEPLISAV to date. In the largest completed clinical trial, known as PHAST (Phase 3 HeplisAv Short-regimen Trial), HEPLISAV met its primary endpoint. The multi-center PHAST trial evaluated more than 2,000 subjects from 11 to 55
years of age in Canada and Germany. This Phase 3 trial evaluated a two-dose regimen of HEPLISAV administered at 0 and 1 month, compared to a three-dose regimen of Engerix-B
®
administered at 0, 1, and 6 months. The primary endpoint was the proportion of subjects who developed protective antibody to hepatitis B after receiving a full
course of vaccination.

Immunogenicity results from this trial demonstrated that subjects receiving HEPLISAV were
seroprotected with fewer doses and at an earlier time point than subjects receiving Engerix-B. Results showed 95% of subjects who received two doses of HEPLISAV at 0 and 1 month developed protective antibody to hepatitis B by 12 weeks, compared to
81% of subjects who received three doses of Engerix-B at 0, 1, and 6 months at 28 weeks. Data from this trial also demonstrate that subjects over 40 years of age receiving two doses of HEPLISAV over one month achieved a seroprotection rate of 92%,
compared to 75% of subjects receiving 3 doses of Engerix-B over six months.

Overall safety results in the PHAST trial showed
the profile of 2 doses of HEPLISAV appeared similar to 3 doses of Engerix-B, with the exception that subjects who received HEPLISAV had a higher risk of developing injection site swelling, redness, and pain compared to those who received Engerix-B.
The incidence of Adverse Events (AE) was 81.9% for the HEPLISAV group, compared to 81.4% for the Engerix-B group. The incidence of Serious Adverse Events (SAEs) was 1.5% for the HEPLISAV group, compared to 2.1% for the Engerix-B group. There were
two cases of systemic vasculitis reported as SAEs in this trial, a case of Wegeners granulomatosis, or c-ANCA vasculitis, in the HEPLISAV group and a case of p-ANCA systemic vasculitis in the Engerix-B group. From March 2008 until September
2009, the two Investigational New Drug (IND) applications for HEPLISAV were placed on clinical hold by the U.S. Food and Drug Administration (the FDA) following the Wegeners granulomatosis SAE that occurred in the HEPLISAV group of
the PHAST trial. In September 2009, the FDA removed the clinical hold on the IND application for individuals with chronic kidney disease.

In October 2010, we reported that HEPLISAV given as two doses over four weeks demonstrated superior seroprotection in persons with diabetes mellitus compared to Engerix-B given as three doses over 24
weeks. The subset analysis of 62 adults with diabetes in our previously reported PHAST Phase 3 multicenter study showed

that at 12 weeks, 84% of adult diabetics treated with HEPLISAV achieved seroprotection as compared to 0% of adult diabetics treated with Engerix-B. At week 28, 93% of the HEPLISAV-treated group
versus 35% in the Engerix-B group achieved seroprotection. HEPLISAVs significantly higher rate of seroprotection was achieved without further immunization past four weeks while the Engerix-B group received a third immunization at 24 weeks.

Commercial Opportunity

Hepatitis B is a chronic disease which can lead to cirrhosis of the liver and hepatocellular carcinoma. There is no cure for hepatitis B and disease prevention through effective vaccines is critical to
reducing the spread of the disease. Available hepatitis B vaccines for adults have several limitations, including:



Slow onset of protectionthe current regimen for adults is usually 3 doses given over 6 months to provide seroprotection of approximately 30%,
75%, and 90% after the first, second, and third doses respectively;



Poor protection in populations that are low responderscurrent vaccines provide less seroprotection to persons over 40 years of age and to
immunocompromised persons, such as end-stage renal disease (ESRD) patients; and



Poor compliance in certain settings only 30% of people receive all 3 doses.

HEPLISAV is designed to address the limitations of current vaccines by providing rapid and superior protection with fewer doses than
currently licensed vaccines.

We estimate the current worldwide market for adult monovalent hepatitis B vaccines exceeds $400
million annually. This market is primarily comprised of GSKs Engerix-B and Mercks Recombivax-HB. Over an estimated $400 million in additional sales are generated by GSKs combined Hepatitis A / Hepatitis B vaccine, Twinrix. Key
market segments include chronic kidney disease (CKD) patients, healthcare workers and first responders, travelers, people with multiple sexual partners or injection drug use, and chronic liver disease patients.

HEPLISAV is being developed initially for patients less responsive to current licensed vaccines, including patients over 40 years of age,
individuals with CKD, HIV, and chronic liver disease. The CKD market is large, growing rapidly, and is recommended for vaccination. In 2008, there were approximately 750,000 ESRD patients in the United States and major European markets and
approximately 150,000 new patients are added annually. Because these patients typically do not respond well to current vaccines, a typical regimen calls for 8 doses of Engerix-B (versus 3 doses in the general population). Even with this
regimen, approximately 35% of these immunocompromised ESRD patients do not respond to vaccination and approximately 27-43% require boosters. As vaccination for these patients occurs regularly at dialysis centers, this is a concentrated,
renewable market that can be served by cost-effective, targeted sales distribution networks.

In addition to the CKD market,
we believe that the potentially differentiating characteristics of HEPLISAV can address key unmet needs in adult hepatitis B vaccination, and may provide an opportunity for growth in under-served market segments such as HIV and chronic liver
disease. The HIV positive market segment shares similar characteristics to the ESRD market. Vaccination is critical due to substantially increased morbidity and mortality from co-infection with HIV and HBV and similar modes of transmission. Because
these patients typically do not respond well to current vaccines, aggressive vaccination regimens and boosters are common. There are approximately two million adults living with HIV in the United States and Europe, with approximately 150,000 new
cases annually. Chronic liver disease can be caused by hepatitis C infection, alcohol or genetics. These patients are also recommended for vaccination, but vaccine coverage rates are low, representing a future opportunity for hepatitis B vaccines to
grow.

We also believe that the profile of HEPLISAV has potential benefits for individuals who need
rapid protection against hepatitis B, including healthcare workers, first responders, travelers and diabetics because HEPLISAV provides higher levels of protection following 30 days of treatment compared to 6 months for current licensed vaccines.

Universal Flu Vaccine

Our Universal Flu vaccine is designed to offer protection against divergent strains as well as increase the efficacy and potentially reduce the antigen content of standard flu vaccines. This unique
approach is based on our proprietary component N8295, which is a fusion protein comprised of two highly conserved influenza antigens, nucleoprotein (NP) and matrix protein 2 (M2e), covalently linked to proprietary second-generation TLR9 agonist.
N8295 is then combined with a conventional flu vaccine:



Conventional flu vaccinesCurrently available flu vaccines typically contain antigens of three flu viruses: two influenza A subtypes and one
influenza B subtype. The exact composition changes every year and is determined by the World Health Organization (WHO) and FDA based upon surveillance and estimates of which types and strains of viruses are likely to circulate. The goal of existing
vaccines is to induce the development of antibodies to provide protection against influenza infection. Our proprietary component could be combined with any flu vaccine, including standard trivalent influenza vaccine (TIV) and vaccines for
emerging strains such as H5N1 or H1N1.



Two highly conserved antigens, NP and M2e, are expected to offer protection against divergent influenza strainsOur Universal Flu vaccine includes
two conserved antigens, NP and M2e, which are present in all flu strains. NP, or nucleoprotein, is highly conserved across human and animal strains, while M2e, the extracellular domain of the matrix 2 protein, is conserved but with some
variations among species. NP induces cytotoxic T-cell protection and M2e induces antibodies that may provide protection against divergent strains.

Dynavax has established a worldwide supply and option agreement with Novartis Vaccines and
Diagnostics, Inc., under which Novartis is supplying trivalent influenza vaccine, an essential component of our Universal Flu vaccine.

Clinical Results

In early December 2010, we reported safety and
immunogenicity data from our Phase 1a clinical trial of N8295. The trial assessed three dose levels of N8295 in a total study population of 39 subjects. The Phase 1a data showed that all doses were safe and generally well tolerated. There were no
dose limiting toxicities, subjects demonstrated positive antibody responses to M2e and NP, and positive T-cell mediated responses to NP were seen. Based on preliminary safety data for the Phase 1a trial, we initiated a Phase 1b study in September
2010 to evaluate the safety of the combination of N8295 and an investigational H5N1 avian influenza vaccine. The Phase 1b study evaluated 54 subjects, including 39 from the Phase 1a dose escalation study of N8295 and 15 from the Phase 1b dose
escalation study of H5N1/N8295. Data from the Phase 1a and the Phase 1b study reported at the World Health Organization 7th Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in February 2011 showed:



N8295 alone or combined with H5N1 vaccine was very safe and generally well tolerated;



The most common adverse events were mild, self-limited injection site reactions;



There were no SAEs;



All N8295 dose groups had an antibody response to M2e, and the placebo group did not;



All N8295 dose groups had an antibody response to NP, and the placebo group did not;

All N8295 dose groups had a cellular immune response to NP, and the placebo group did not;



The addition of N8295 to a non-immunogenic dose of H5N1 vaccine resulted in H1 responses in all N8295 dose groups.
1

Commercial Opportunity

Human viral influenza is an acute respiratory disease with high morbidity and mortality that occurs in annual epidemics worldwide. There are an estimated 30,000 to 40,000 viral influenza-associated deaths
per year in the United States, primarily in those over 65 years of age. Influenza pandemics occur infrequently, on average every 30 to 40 years, but it is estimated that the next pandemic could result in millions of deaths worldwide. Analysts
estimate the current worldwide market opportunity for seasonal influenza vaccines to be approximately $3 billion annually.

Standard flu vaccines can provide protection against the flu strains predicted to be prevalent during a season. The efficacy of these
vaccines is often decreased by unpredictable changes in the actual strains causing influenza. Current vaccines are also least effective in those who need prevention the most, the elderly and others with weaker immune systems. Pandemic vaccination is
further complicated by the need to produce large quantities of vaccine in a short time period.

Our Universal Flu vaccine
candidate is designed to offer protection against divergent influenza strains, increase the efficacy of standard vaccines and potentially reduce the antigen content of vaccine to extend the quantity available during a pandemic.

SD-101 Hepatitis C Therapy

SD-101, our hepatitis C therapy, has completed a Phase 1b clinical trial and is part of the portfolio of development programs that are available for partnership. This therapy utilizes a novel Type C TLR9
agonist based on our second-generation ISS. SD-101 is designed to be used in combination with current or emerging therapies to reduce hepatitis C virus (HCV) viral replication and induce a long-lasting immune response. In December 2009, we completed
the acquisition of Symphony Dynamo, Inc., which provided us with full development and commercialization rights to SD-101.

Data from a Phase 1b trial and from an
in vitro
study of SD-101s mechanism of action show that SD-101 is safe and
well-tolerated, and induces both IFN-lambda and IFN-alpha at concentrations producing antiviral activity.

DV-601 Hepatitis
B Therapy

DV-601, our proprietary hepatitis B therapy, is completing a Phase 1b clinical trial and is
part of the portfolio of development programs that are available for partnership. Our treatment approach combines both the surface and core HBV antigens with ISCOMATRIX
®
adjuvant originally entered into development by Rhein Biotech prior to its acquisition by Dynavax in 2006. DV-601 is designed to induce an immune response against
HBV-infected cells and if proven to be safe and effective, may offer an alternative therapeutic option for patients chronically infected with HBV. We have retained all commercial rights to this product.

The Phase 1b dose escalation study assessed safety and the immunologic and virologic responses in 14 subjects with chronic hepatitis B
infection, including six patients that were HBeAg negative and eight patients who were HBeAg positive, and found:



The therapeutic regimen was safe and generally well tolerated at all dose levels;



Most common systemic reactions were fatigue and malaise. No SAEs were recorded;

DV601 was found to elicit immune responses at all dose levels, and anti-HBe antibodies were elicited in two of eight (2/8) patients;



Anti-HBs antibodies were elicited in four of 14 (4/14) patients;



Amongst the eight HBeAg positive patients, two had HBeAg clearance, and one of those individuals also had HBsAg clearance;



Three patients are still in the follow-up observation period.

DV1179 (IRS) for Autoimmune and Inflammatory Diseases

We are developing DV1179, a bifunctional inhibitor of TLR7 and TLR9, under a worldwide strategic alliance with GSK. Our IRS program is focused on novel TLR inhibitors for diseases such as lupus,
psoriasis, and rheumatoid arthritis. We plan to initiate a Phase 1 clinical study with GSK in 2011.

AZD1419 Asthma Therapy

We have developed AZD1419, a novel candidate drug for asthma, under our worldwide collaboration with AstraZeneca. AZD1419
utilizes our proprietary second-generation ISS and represents a new strategy for the treatment of allergic respiratory diseases such as asthma. This therapy is designed to modify the course of these diseases by changing the basic immune response to
environmental allergens, such as house dust and pollens, leading to prolonged reduction in asthma symptoms.

Pharmaceutical Partnerships
and Other Funding Agreements

Our objective is to discover novel therapies based on our proprietary technologies and
develop a diversified pipeline of product candidates to build a product-based business. To reach this objective, an important part of our strategy is to establish partnerships with leading pharmaceutical companies and enter into funding agreements.
Our pharmaceutical partners provide valuable resources, expertise, and abilities that allow us to further advance the development of our product candidate programs. We also have funding agreements with U.S. government institutions.

GlaxoSmithKline

In December 2008, we entered into a worldwide strategic alliance with GSK to discover, develop, and commercialize endosomal TLR inhibitors for diseases such as lupus, psoriasis, and rheumatoid arthritis.
We received an initial payment of $10 million and agreed to conduct research and early clinical development in up to four programs. We are eligible to receive future potential development and commercialization milestones totaling approximately $200
million per program. GSK can exercise its exclusive option to license each program upon achievement of proof-of-concept or earlier upon certain circumstances. After exercising its option, GSK would carry out further development and commercialization
of these products. We are eligible to receive royalties from the mid-single digits up to the high-teens based on product sales and have retained an option to co-develop and co-promote one specified product under the collaboration.

Absent early termination, the agreement will expire when all of GSKs payment obligations expire. Either party may terminate the
agreement early upon written notice if the other party commits an uncured material breach of the agreement. Either party may terminate the agreement in the event of insolvency of the other party. GSK also has the option to terminate the agreement
without cause, upon prior written notice within a specified window of time dependent upon stage of clinical development of the programs.

In September 2006, we entered into a worldwide research and license agreement with AstraZeneca to discover and develop TLR9 agonist
products for asthma and COPD. We are eligible to receive a total of $136 million in payments and, upon commercialization of these products, royalties up to the high-teens based on product sales, if any. AstraZeneca has the right to sublicense
its rights with our prior consent. We also have the opportunity to co-promote in the United States. In September 2008, we received a $4.5 million milestone payment from AstraZeneca for the nomination of the first candidate drug, AZD1419, for asthma
and have completed IND-enabling studies.

Absent early termination, the agreement will expire when all of AstraZenecas
payment obligations expire. AstraZeneca has the right to terminate the agreement at any time upon prior written notice and either party may terminate the agreement early upon written notice if the other party commits an uncured material breach of
the agreement.

Novartis Vaccines and Diagnostics, Inc.

In July 2008, we entered into a supply and option agreement with Novartis related to our Universal Flu vaccine. Under this agreement,
Novartis is supplying trivalent influenza vaccine, an essential component of our Universal Flu vaccine. We agreed to conduct early-stage development through a defined proof-of-concept. If Novartis exercises the right to negotiate and enter a further
agreement for development and commercialization, we would retain co-commercialization rights in the United States and receive product royalties on product sales outside of the United States, if any. If the option is not exercised or the parties do
not enter into a further agreement, Novartis remains committed to providing commercial supply of trivalent influenza vaccine with pre-agreed commercial terms and we retain the right to independently continue with late-stage development and
commercialization, provided we do not partner with a company that produces or markets a trivalent influenza vaccine product in the United States.

Either party may terminate the agreement if (a) the other party commits a material uncured breach, (b) there is change in control of the other party, (c) certain specified clinical or
regulatory objectives are not achieved or certain development events or failures occur, or (d) Dynavax ceases development of the product candidate for a certain length of time.

National Institutes of Health (NIH) and Other Funding

In September 2008, we were awarded a $17 million contract to develop our advanced ISS technology using TLR9 agonists as vaccine adjuvants. This five-year contract was awarded by the NIHs National
Institute of Allergy and Infectious Diseases (NIAID) and supports adjuvant development for biodefense vaccines, including anthrax as well as other diseases. NIAID is funding 100% of the total $17 million cost of our program under Contract No.
HHSN272200800038C. The NIH may terminate performance of work under the contract if the Contracting Officer determines that a termination is in the governments interest or if the Company defaults in performing and fails to cure after notice.

During 2010, we announced a grant from the NIAID to take a systems biology approach to study the differences between
individuals that do or do not respond to vaccination against the HBV. This study will be one of several projects covered in a five-year, $17.6 million grant to the Baylor Institute of Immunology Research in Dallas as part of the Human Immune
Phenotyping Centers program.

We also received the award of a $0.6 million grant from the NIH to explore the feasibility of
developing a universal vaccine to prevent infection by human papilloma virus (HPV). In contrast to the two approved HPV vaccines that target approximately 70% of HPV strains, our goal is to develop a vaccine that provides immunity to nearly all
cancer-causing strains of HPV. Each year, 470,000 new cases of cervical cancers are diagnosed worldwide, and 250,000 deaths are attributable to cervical cancers.

Finally, $0.7 million in grants under The Patient Protection and Affordable Care Act of 2010
were awarded to us to cover research and development costs from 2009 and 2010 for our qualified therapeutic discovery projects including HEPLISAV.

For our TLR inhibitor programs, since 2004 we have been awarded $2.8 million in grants from the NIH and Alliance for Lupus Research.

Intellectual Property

Our commercial success depends in part on our
ability to obtain and maintain proprietary protection for our drug candidates, technology and know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. In addition to
seeking patent protection in the United States, we generally file patent applications in Australia, Canada, Japan, Western European countries and additional foreign countries on a selective basis in order to further protect the inventions that we or
our partners consider important to the development of our foreign business. We also rely on trade secrets and contracts to protect our proprietary information.

As of December 31, 2010, our intellectual property portfolio included 16 issued U.S. patents, over 100 issued or granted foreign patents and over 100 additional pending U.S. and foreign patent
applications claiming compositions and formulations of ISS and IRS, their methods of use or processes for their manufacture. Some of these patents and applications are exclusively licensed to us under two agreements with the Regents of the
University of California.

We have an issued U.S. patent covering the ISS contained in our HEPLISAV investigational vaccine
that will expire in 2018, unless extended, and corresponding issued patents in several major European and other countries. We own or have an exclusive license to U.S. and foreign patent applications pending for each of our other product candidates
and/or their uses. At present, it is not known or determinable whether patents will issue from any of these applications or what the specific expiration dates would be for any patents that do issue.

Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance
and the legal term of patents in the countries in which they are obtained. Generally, patents issued in the United States are effective for:



the longer of 17 years from the issue date or 20 years from the earliest effective filing date, if the patent application was filed prior to
June 8, 1995; and



20 years from the earliest effective filing date, if the patent application was filed on or after June 8, 1995.

In addition, in certain instances, a patent term can be extended to recapture a portion of the term effectively lost as a result of the
FDA regulatory review period. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is 20 years from the earliest effective filing date. Our patent estate, based on patents existing now and
expected by us to issue based on pending applications, will expire on dates ranging from 2017 to 2030.

The actual protection
afforded by a patent varies on a product-by-product basis, from country-to-country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory related extensions, the availability of legal
remedies in a particular country, and the validity and enforceability of the patents.

Because patent applications in the
United States and many foreign jurisdictions typically are not published until 18 months after filing and publications of discoveries in the scientific literature often lag behind actual discoveries, we cannot be certain that we were the first to
make the inventions claimed in each of our issued

patents or pending patent applications or that we were the first to file for protection of the inventions set forth in these patent applications. The U.S. Patent and Trademark Office may declare
interference proceedings to determine the priority of inventions with respect to our patent applications and those of other parties or reexamination or reissue proceedings to determine if the scope of a patent should be narrowed.

Our commercial success depends significantly on our ability to operate without infringing patents and proprietary rights of third
parties. A number of pharmaceutical companies and biotechnology companies, including Pfizer, Inc., as well as universities and research institutions, may have filed patent applications or may have been granted patents that cover inventions similar
to the inventions owned or licensed to us. We cannot determine with certainty whether patents or patent applications of other parties may materially affect our ability to make, use or sell any products. If another party controls patents or patent
applications covering our products, we may not be able to obtain the rights we need to those patents or patent applications in order to commercialize our products. Two of our potential competitors, Merck and GSK, are exclusive licensees of broad
patents covering hepatitis B surface antigen, a component of HEPLISAV. In addition, the Institut Pasteur also owns or has exclusive licenses to patents covering hepatitis B surface antigen. While some of these patents have expired or will soon
expire outside the United States, they remain in force in the United States.

Litigation may be necessary to enforce patents
issued or licensed to us or to determine the scope or validity of another partys proprietary rights. The existence of third-party patent applications and patents could significantly reduce the coverage of the patents owned by or licensed to us
and limit our ability to obtain meaningful patent protection. For example, Pfizer has issued U.S. and foreign patent claims as well as patent claims pending with the U.S. Patent and Trademark Office and foreign patent offices that, if held to be
valid, could require us to obtain a license in order to commercialize one or more of our formulations of ISS. To the extent we are able to commercialize HEPLISAV in the United States while these patents remain in force, Merck, GSK or the Institut
Pasteur may bring claims against us. Litigation or any other proceedings, such as patent interferences, could result in substantial costs to and diversion of effort by us, and an adverse outcome in a court or patent office could subject us to
significant liabilities, require disputed rights to be licensed from other parties, or require us to cease using some of our technology. We may not prevail in any of these actions or proceedings.

In addition, other parties may duplicate, design around or independently develop similar or alternative technologies to ours or our
licensors.

We may rely, in some circumstances, on trade secrets and confidentiality agreements to protect our technology.
Although trade secrets are difficult to protect, wherever possible, we use confidential disclosure agreements to protect the proprietary nature of our technology. Our policy is to require each of our commercial partners, employees, consultants and
advisors to enter into an agreement before beginning their employment, consulting or advisory relationship with us that in general provides that the individuals must keep confidential and not disclose to other parties any of our confidential
information developed or learned by the individuals during the course of their relationship with us except in limited circumstances. These agreements also generally provide that we own all inventions conceived by the individuals in the course of
rendering their employment or services to us. However, there can be no assurance that these agreements will not be breached, that we will have adequate remedies for any breach, or that our trade secrets and/or proprietary information will not
otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants or contractors use intellectual property owned by others in their work for us, disputes may also arise as to the rights in related or
resulting know-how and inventions.

Under the terms of our license agreements with the Regents of the University of
California, we are required to pay license fees, make milestone payments, share a portion of fees from third party partnerships up to a specified amount and pay low single-digit royalties on net sales resulting from successful products originating
from the licensed technologies. To date, we have paid the University of California a total of $1.6 million in license fees, shared third party partnership fees and milestone payments under these agreements. We estimate the total potential milestone
payments payable for each such product will total approximately $3.1 million, not

including royalties. We may terminate these agreements in whole or in part on 60 days advance notice. The Regents of the University of California may terminate these agreements if we are in
breach for failure to make royalty payments, meet diligence requirements, produce required reports or fund internal research and we do not cure such breach within 60 days after being notified of the breach. Otherwise, the agreements generally
continue in effect until the last patent claiming a product licensed under the agreement or its manufacture or use expires, or in the absence of patents, until the date the last patent application claiming a licensed product is abandoned.

Competition

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong
emphasis on proprietary products. Many of our competitors, including biotechnology and pharmaceutical companies, academic institutions and other research organizations, are actively engaged in the discovery, research and development of products that
could compete directly or indirectly with our products under development.

HEPLISAV, a two-dose hepatitis B vaccine, if
approved and commercialized, will compete directly with three-dose marketed vaccines produced by GSK and Merck & Co. (Merck), among others. There are also modified schedules of conventional hepatitis B vaccines for limited age ranges that
are approved in the European Union and United States. In addition, HEPLISAV will compete against a number of multivalent vaccines that simultaneously protect against hepatitis B in addition to other diseases.

Our Universal Flu vaccine, if developed, approved and commercialized, will compete with traditional and emerging influenza vaccines from
companies currently marketing these products, including: GSK, Novartis, Sanofi Pasteur, MedImmune/AstraZeneca and CSL Ltd. In addition, there are several companies developing potentially competing universal vaccines for influenza, including Sanofi
Pasteur, VaxInnate, Merck and Vical.

Our hepatitis C therapy, SD-101, if developed, approved, and commercialized, may compete
directly with interferon alpha, products currently marketed by Roche and Merck. Other companies, such as Vertex Pharmaceuticals, Inc./Tibotec Pharmaceuticals, Gilead Sciences, Inc. (Gilead), Merck, Bristol-Myers Squibb, and Roche/Pharmasset,
Inc./InterMune, Inc. are developing direct acting antiviral therapy, including NS5A inhibitors, protease inhibitors and polymerase inhibitors, and long-acting interferons. As these products may enter the market potentially within the next one to
five years, combination therapy is likely to evolve. Novel therapies aim to improve the efficacy, safety and convenience of current hepatitis C treatment and may compete both directly and indirectly with SD-101.

Our therapy for autoimmune and inflammatory diseases, DV1179, is a bifunctional inhibitor of TLR7 and TLR9 that if developed, approved and commercialized will compete with key biologic therapies from
companies such as Genentech, Inc. (Genentech), Biogen Idec, Roche, Abbott Laboratories and Human Genome Sciences/GSK. In addition, our product would compete with generic drugs commonly used to treat autoimmune diseases, including corticosteroids,
NSAIDs, antimalarials and immunosuppressive agents. Other companies, such as MedImmune, Genentech, Idera, Pfizer and UCB/Immunomedics, Inc., are developing anti-IFN-alpha-antibodies, B-cell targeted antibodies, immunosuppressants, and other TLR
inhibitors that may compete directly with our product candidate.

monoclonal antibodies, including those marketed by Merck, Genentech, Novartis, AstraZeneca and GSK. In addition, directly competing products are in development by Sanofi-Aventis and Idera
Pharmaceuticals.

Many of the entities developing and marketing these competing products have significantly greater financial
resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing than we do. Smaller or early-stage companies may also prove to be significant
competitors, particularly for collaborative agreements with large, established companies and access to capital. These entities may also compete with us in recruiting and retaining qualified scientific and management personnel, as well as in
acquiring technologies complementary to or necessary for our programs.

Regulatory Considerations

The advertising, labeling, storage, record-keeping, safety, efficacy, research, development, testing, manufacture, promotion, marketing
and distribution of our potential products are subject to extensive regulation by numerous governmental authorities in the United States and other countries. In the United States, pharmaceutical and biological products are subject to rigorous review
by the FDA under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act and other federal statutes and regulations. The steps ordinarily required by the FDA before a new drug or biologic may be marketed in the United States are
similar to steps required in most other countries and include but are not limited to the following:

submission to the FDA of an IND application for a new drug or biologic which must become effective before clinical trials may begin;



performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug or biologic for each proposed
indication;



demonstration of the consistent manufacturing of a drug substance and drug product;



the submission of a new drug application (NDA) or a biologics license application (BLA) to the FDA; and



FDA review and approval of the NDA or BLA before any commercial marketing, sale or shipment of the drug.

If we do not comply with applicable requirements, U.S. regulatory authorities may fine us, require that we recall our products, seize our
products, require that we totally or partially suspend the production of our products, refuse to approve our marketing applications, criminally prosecute us, and/or revoke previously granted marketing authorizations.

To secure FDA approval, we must submit extensive non-clinical and clinical data, adequate evidence of a product manufactured by a
well-controlled process that is safe and effective for its intended use, and other supporting information to the FDA for each indication. The number of preclinical studies and clinical trials that will be required for FDA and foreign regulatory
agency approvals varies depending on the product candidate, the disease or condition for which the product candidate is in development and regulations applicable to any particular drug candidate. Data obtained from preclinical and clinical
activities are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval or clearance. Further, the results from preclinical testing and early clinical trials may not be predictive of results obtained in later
clinical trials. In addition, the development of the drug substance and drug product may require manufacturing modifications to ensure future regulatory acceptance. The approval process takes many years, requires the expenditures of substantial
resources, involves post-marketing surveillance and may involve requirements for additional post-marketing studies. The FDA may also require post-marketing testing and surveillance to monitor the effects of approved products or place conditions on
any approvals that could restrict the commercial applications of these products. The FDA may withdraw product approvals if we do not continue to comply with regulatory standards

or if problems occur following initial marketing. Delays experienced during the governmental approval process may materially reduce the period during which we will have exclusive rights to
exploit patented products or technologies. Delays can occur at any stage of drug development and as a result of many factors, certain of which are not under our control, including but not limited to the following:



lack of efficacy, or incomplete or inconclusive results from clinical trials;



unforeseen safety issues;



failure by investigators to adhere to protocol requirements, including patient enrollment criteria;



slower than expected rate of patient recruitment;



failure by subjects to comply with trial protocol requirements;



inability to follow patients adequately after treatment;



inability to qualify and enter into arrangements with third parties to manufacture sufficient quality and quantities of materials for use in clinical
trials;



failure by a contract research organization to fulfill contractual obligations; and



adverse changes in regulatory policy during the period of product development or the period of review of any application for regulatory approval or
clearance.

Non-clinical studies involve laboratory evaluation of product characteristics and animal studies
to assess the initial efficacy and safety of the product. The FDA, under its good laboratory practices regulations, regulates non-clinical studies. Violations of these regulations can, in some cases, lead to invalidation of those studies, requiring
these studies to be repeated. The results of the non-clinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application, which must be approved by the FDA before we can commence
clinical investigations in humans. Unless the FDA objects to an IND application, the IND application will become effective 30 days following its receipt by the FDA. Clinical trials involve the administration of the investigational product to humans
under the supervision of a qualified principal investigator. We must conduct our clinical trials in accordance with good clinical practice under protocols submitted to the FDA as part of the IND application. In addition, each clinical trial must be
approved and conducted under the auspices of an investigational review board and with patient informed consent. The investigational review board will consider, among other things, ethical factors, the safety of human subjects and the possibility of
liability of the institution conducting the trial.

The stages of the FDA regulatory process include research and preclinical
studies and clinical trials in three sequential phases that may overlap. Research and preclinical studies do not involve the introduction of a product candidate in human subjects. These activities involve identification of potential product
candidates, modification of promising candidates to optimize their biological activity, as well as preclinical studies to assess safety and effectiveness in animals. In clinical trials, the product candidate is administered to humans. Phase 1
clinical trials typically involve the administration of a product candidate into a small group of healthy human subjects. These trials are the first attempt to evaluate a drugs safety, determine a safe dose range and identify side effects.
During Phase 2 trials, the product candidate is introduced into patients who suffer from the medical condition that the product candidate is intended to treat. Phase 2 studies are designed to evaluate whether a product candidate shows evidence of
effectiveness, to further evaluate dosage, and to identify possible adverse effects and safety risks. When Phase 2 evaluations demonstrate that a product candidate appears to be both safe and effective, Phase 3 trials are undertaken to confirm a
product candidates effectiveness and to test for safety in an expanded patient population. If the results of Phase 3 trials appear to confirm effectiveness and safety, the data gathered in all phases of clinical trials form the basis for an
application for FDA regulatory approval of the product candidate.

We and all of our contract manufacturers are required to
comply with the applicable FDA current Good Manufacturing Practice (GMP) regulations. Manufacturers of biologics also must comply with FDAs general

biological product standards. Failure to comply with the statutory and regulatory requirements subjects the manufacturer to possible legal or regulatory action, such as suspension of
manufacturing, seizure of product or voluntary recall of a product. Good manufacturing practice regulations require quality control and quality assurance as well as the corresponding maintenance of records and documentation. Prior to granting
product approval, the FDA must determine that our or our third party contractors manufacturing facilities meet GMP requirements before we can use them in the commercial manufacture of our products. In addition, our facilities are subject to
periodic inspections by the FDA for continued compliance with GMP requirements during clinical development as well as following product approval. Adverse experiences with the product must be reported to the FDA and could result in the imposition of
market restriction through labeling changes or in product removal.

Outside the United States, our ability to market a product
is contingent upon receiving marketing authorization and pricing or reimbursement approval from the appropriate regulatory authorities. The requirements governing the conduct of clinical trials, manufacturing, marketing authorization, pricing and
reimbursement vary widely from country to country.

At present, foreign marketing authorizations may be applied for at a
national level, although within the European Union centralized registration procedures are mandatory for biotechnology and some other drugs and are available to companies wishing to market a product in more than one European Union member state. The
regulatory authority generally will grant marketing authorization if it is satisfied that we have presented it with adequate evidence of a product manufactured by a well-controlled process that is safe and effective for its intended use.

We are also subject to various federal, state and local laws, regulations and recommendations relating to safe working conditions,
laboratory and manufacturing practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research.
We cannot accurately predict the extent of government regulation that might result from any future legislation or administrative action.

Research and Development

Conducting a significant amount of research and development has been central to our business model. Our research and development expenses
were $53.6 million, $38.7 million and $44.8 million for the years ended December 31, 2010, 2009 and 2008, respectively.

Environment

We have made, and will continue to make, expenditures for environmental compliance and protection. We do not expect that
expenditures for compliance with environmental laws will have a material effect on our capital expenditures or results of operations in the future.

Employees

As of December 31, 2010, we had 128 full-time employees,
including 21 Ph.D.s, 5 M.D.s and 10 others with advanced degrees. Of the 128 employees, 100 were dedicated to research and development activities. None of our employees is subject to a collective bargaining agreement, and we believe our relations
with our employees are good.

Available Information and Website Address

Our website address is www.dynavax.com. We make available free of charge through our website, our annual report on Form 10-K, quarterly
reports on Form 10-Q, current reports on Form 8-K, and all amendments to these reports as soon as reasonably practicable after filing, by providing a hyperlink to the SECs website directly to our reports. The contents of our website are not
incorporated by reference into this report.

This Annual
Report on Form 10-K contains forward-looking statements concerning our future products, product candidates, timing of development activities, regulatory strategies, intellectual property position, expenses, revenues, liquidity and cash needs, as
well as our plans and strategies. These forward-looking statements are based on current expectations and we assume no obligation to update this information. Numerous factors could cause our actual results to differ significantly from the results
described in these forward-looking statements, including the following risk factors.

Risks Related to our Finances and Capital
Requirements

We have incurred substantial losses since inception and do not have any commercial products that generate revenue.

We have experienced significant net losses in each year since our inception. Our accumulated deficit was $316.9
million as of December 31, 2010. To date, our revenue has resulted from collaboration agreements, services and license fees from customers of Dynavax Europe, and government and private agency grants. The grants are subject to annual review
based on the achievement of milestones and other factors. We anticipate that we will incur substantial additional net losses in future years as a result of our investment in research and development activities.

We do not have any products that generate revenue. There can be no assurance whether HEPLISAV can be further developed, financed or
commercialized in a timely manner without significant additional studies or patient data or significant expense; whether development efforts will be sufficient to support approval of HEPLISAV; or whether the market for HEPLISAV will be sufficient
for us to reach profitability.

Clinical trials for certain of our other product candidates are ongoing, and our other product
candidates may never be commercialized or achieve profitability. Our ability to generate revenue depends upon demonstrating in clinical trials that our product candidates are safe and effective, obtaining regulatory approvals for our product
candidates, and entering into and maintaining successful collaborative relationships.

If we are unable to generate
significant revenues or achieve profitability, we may be required to reduce or discontinue our current and planned operations, enter into a transaction that constitutes a change in control of the company, or raise additional capital on less than
favorable terms. Additionally, if we continue to incur substantial additional net losses without additional equity funding, we will continue to deplete our stockholders equity, and if such equity balance falls below the listing requirement
threshold of $2.5 million for the NASDAQ Capital Market, we may be delisted.

We require substantial additional capital to continue
development of our product candidates, in particular our most advanced candidate, HEPLISAV. We cannot be certain that funds will be available and, if they are not available, we may not be able to continue as a going concern which may result in
actions that could adversely impact our stockholders.

In order to continue development of our product candidates,
particularly HEPLISAV, we still need to raise significant additional funds. This may occur through our September 2010 Purchase Agreement (the Purchase Agreement) with Aspire Capital Fund, LLC (Aspire Capital), future public
or private financings and/or strategic alliance and licensing arrangements. We expect to continue to spend substantial funds in connection with:



development and manufacturing of our product candidates, particularly HEPLISAV;

We currently estimate that we will have sufficient resources to meet our anticipated cash
needs through the next twelve months based on cash and cash equivalents and marketable securities on hand at December 31, 2010, anticipated revenues from existing agreements and the funding available to us under the Purchase Agreement.

Sufficient additional financing through future public or private financings, strategic alliance and licensing arrangements or
other financing sources may not be available on acceptable terms, or at all. Additional equity financings, if completed, could result in significant dilution or otherwise adversely affect the rights of existing shareholders. If adequate funds are
not available in the future, we would need to delay, reduce the scope of, or put on hold the HEPLISAV program or other development programs while we seek strategic alternatives.

The sale of our common stock to Aspire Capital may cause dilution to our existing stockholders and the sale of the shares of common stock acquired by Aspire Capital could cause the price of our
common stock to decline.

Shares offered to Aspire Capital under the Purchase Agreement may be sold over a period of up
to 25 months from the date of the Purchase Agreement subject to the limitations and conditions of the agreement. The number of our shares ultimately offered for sale by Aspire Capital is dependent upon the number of shares we elect to sell to Aspire
Capital under the Purchase Agreement and the number of authorized shares we have available for sale. Aspire Capital may ultimately purchase all, some or none of the remaining common stock provided for in the Purchase Agreement. As of
December 31, 2010, we have issued 2,350,000 shares of common stock under the Purchase Agreement. After Aspire Capital has acquired shares pursuant to the Purchase Agreement, it may sell all, some or none of those shares.

On any business day on which the closing sale price of our common stock exceeds $1.00 per share, we have a right to sell up to a maximum
of 150,000 shares per day under the Purchase Agreement, which total may be increased by mutual agreement up to an additional 1,000,000 shares per day. The capital available under the Purchase Agreement may not be sufficient to fund our
current need for capital. The extent to which we rely on Aspire Capital as a source of funding will depend on a number of factors, including the prevailing market price of our common stock and the extent to which we are able to secure working
capital from other sources.

Depending upon market liquidity at the time, sales of shares of our common stock by Aspire
Capital may cause the trading price of our common stock to decline. In addition, sales to Aspire Capital by us pursuant to the Purchase Agreement may result in dilution to the interests of other holders of our common stock. The sale of a substantial
number of shares of our common stock to Aspire Capital, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect
sales. However, we have the right to control the timing and amount of any sales of our shares to Aspire Capital and the Purchase Agreement may be terminated by us at any time at our discretion without any cost to us.

Our independent registered public accountants have indicated that our financial condition raises substantial doubt as to our ability to continue as
a going concern.

Our independent registered public accounting firm has included in their audit opinion on our
consolidated financial statements for the year ended December 31, 2010 a statement with respect to substantial doubt regarding our ability to continue as a going concern. Our consolidated financial statements have been prepared assuming the
Company will continue to operate as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. If we became unable to continue as a going concern, we may have to liquidate our
assets and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our consolidated financial statements.

The success of our product candidates depends on timely achievement of successful clinical results, adequate evidence of a product manufactured by a well-controlled process that is safe and
effective for its intended use and regulatory approval. Failure to obtain regulatory approvals could require us to discontinue operations.

None of our product candidates have been approved for sale by any regulatory agency. Any product candidate we develop is subject to extensive regulation by federal, state and local governmental
authorities in the United States, including the U.S. Food and Drug Administration (FDA) and by foreign regulatory agencies. Our success is primarily dependent on our ability to timely enroll patients in clinical trials, achieve
successful clinical results, provide adequate evidence of a product manufactured by a well-controlled process that is safe and effective for its intended use, and obtain regulatory approvals for our most advanced product candidates. Approval
processes in the United States and in other countries are uncertain, can take many years and require the expenditure of substantial resources.

We will need to demonstrate in clinical trials that a product candidate is safe and effective before we can obtain the necessary approvals from the FDA and foreign regulatory agencies. If we identify any
safety issues associated with our product candidates, we may be restricted from initiating further trials for those products. Moreover, we may not see sufficient signs of efficacy in those studies.

The FDA or foreign regulatory agencies may require us to conduct additional clinical trials prior to approval. Despite the time and money
expended, regulatory approvals are uncertain. In addition, failure to timely and successfully complete clinical trials and show that our products are safe and effective would have a material adverse effect on our business and results of operations.
Even if approved, the labeling approved by the relevant regulatory authority for a product may restrict to whom we may market the product, which could significantly limit the commercial opportunity for such product.

Prior to granting product approval, the FDA must determine that our or our third party contractors manufacturing facilities meet
GMP requirements before we can use them in the commercial manufacture of our products. We and all of our contract manufacturers are required to comply with the applicable FDA GMP current regulations. Manufacturers of biologics also must comply with
FDAs general biological product standards. Failure to comply with the statutory and regulatory requirements subjects the manufacturer to possible legal or regulatory action, such as suspension of manufacturing, seizure of product or voluntary
recall of a product. Good manufacturing practice regulations require quality control and quality assurance as well as the corresponding maintenance of records and documentation.

Our clinical trials may be extended, suspended, delayed or terminated at any time. Even short delays in the commencement and progress of our trials may lead to substantial delays in the regulatory
approval process for our product candidates, which will impair our ability to generate revenues.

We may extend,
suspend or terminate clinical trials at any time for various reasons, including regulatory actions by the FDA or foreign regulatory agencies, actions by institutional review boards, failure to comply with good clinical practice requirements,
concerns regarding health risks to test subjects, failure to enroll patients in a timely manner, or delays due to manufacturing an inadequate supply of the product candidate. Even a short delay in a trial for any product candidate could require us
to delay commencement or continuation of a trial until the target population is available for testing, which could result in a delay of a year or more. The FDA may require larger or additional clinical trials for our HEPLISAV product candidate than
we currently expect before granting regulatory approval, if at all.

Our registration and commercial timelines depend on successful completion of current and
planned clinical trials, successful results from such trials, and further discussions with the FDA and corresponding foreign regulatory agencies. Any extension, suspension, modification, termination or unanticipated delays of our clinical trials
could:

cause us to abandon the development of the affected product candidate; or



limit our ability to obtain additional financing on acceptable terms, if at all.

We rely on contract research organizations to conduct our clinical trials. If these third parties do not fulfill their contractual obligations or
meet expected deadlines, our planned clinical trials may be delayed and we may fail to obtain the regulatory approvals necessary to commercialize our product candidates.

We rely on third parties to conduct our clinical trials. If these third parties do not perform their obligations or meet expected
deadlines our planned clinical trials may be extended, delayed, modified or terminated. Any extension, delay, modification or termination of our clinical trials could delay or otherwise adversely affect our ability to commercialize our products and
could have a material adverse effect on our business and operations.

HEPLISAV and most of our earlier stage programs rely on ISS-based
technology. Serious adverse safety data relating to either 1018 ISS or other ISS-based technology may require us to reduce the scope of or discontinue our operations.

HEPLISAV is based on our 1018 ISS compound, and most of our research and development programs use ISS-based technology. If any of our product candidates in clinical trials produce serious adverse safety
data, we may be required to delay, discontinue or modify our clinical trials or our clinical trial strategy. For example, from March 2008 until September 2009, the two investigational new drug (IND) applications for HEPLISAV were placed
on clinical hold by the FDA following a serious adverse event that occurred in one of our clinical trials. In September 2009, the FDA removed the clinical hold on the IND application for individuals with chronic kidney disease but the other IND
application for HEPLISAV remains on clinical hold. In addition, most of our clinical product candidates contain ISS, and if a common safety risk across therapeutic areas were identified, it may hinder our ability to enter into potential
collaborations and if adverse safety data are found to apply to our ISS-based technology as a whole, we may be required to significantly reduce or discontinue our operations.

We rely on our facility in Düsseldorf, Germany and third parties to supply materials necessary to manufacture our clinical product candidates. We have limited experience in manufacturing
sufficient quantities of ISS for our clinical trials and rely on limited third parties to produce the ISS we need for our clinical trials. Additionally, we have limited experience in manufacturing our product candidates in commercial quantities. If
we reduce our clinical product candidates, we may not require this manufacturing capacity.

We rely on a number of
third parties for the multiple steps involved in the manufacturing process of our product candidates, including ISS, the production of certain antigens, the combination of the antigens and ISS and the fill and finish. Termination or interruption of
these relationships may occur due to circumstances that are outside of our control, resulting in higher cost or delays in our product development efforts.

We have relied on a limited number of suppliers to produce ISS for clinical trials and a
single supplier to produce our 1018 ISS for HEPLISAV. To date, we have manufactured only small quantities of ISS and 1018 ISS ourselves for development purposes. If we were unable to maintain our existing source for 1018 ISS, we would have to
establish an alternate qualified manufacturing capability, which would result in significant additional operating costs and delays in developing and commercializing our product candidates, particularly HEPLISAV. We or other third parties may not be
able to produce 1018 ISS at a cost, quantity and quality that are available from our current third-party supplier.

We
currently utilize our facility in Düsseldorf to manufacture the hepatitis B surface antigen for HEPLISAV. The commercial manufacturing of vaccines and other biological products is a time-consuming and complex process, which must be performed in
compliance with current GMP regulations. We may not be able to comply with these and comparable foreign regulations, and our manufacturing process may be subject to delays, disruptions or quality control/quality assurance problems. Noncompliance
with these regulations or other problems with our manufacturing process may limit or delay the development or commercialization of our product candidates and could result in significant expense. Moreover, if our HEPLISAV clinical trials are
sufficient for approval and depending on the level of market acceptance of the product, we may not have the capacity in our existing facility to meet all of our commercial supply needs in the future.

If HEPLISAV cannot be successfully developed or is not commercially viable, we will have to use the Düsseldorf facility for
alternative manufacturing or research activities that may not fully utilize the facilitys capacity, resulting in continued operating costs that may not be offset by corresponding revenues. We may also consider other alternatives for the
Düsseldorf facility, including its sale or closure, which would result in certain costs of disposal or discontinuation of operations. Discontinuation of operations in Düsseldorf would be complex, expensive, time-consuming and difficult to
execute without significant additional costs due to, among other things, international legal and tax considerations related to those operations. As a result, we may not realize cost savings associated with closure of the Düsseldorf operations,
if at all.

If we receive regulatory approval for our product candidates, we will be subject to ongoing FDA and foreign regulatory
obligations and continued regulatory review.

We and our third party suppliers are required to comply with applicable
current GMP regulations and other international regulatory requirements. The regulations require that our product candidates be manufactured and our records maintained in a prescribed manner with respect to manufacturing, testing and quality
control/quality assurance activities. Suppliers of key components and materials must be named in a BLA submitted to the FDA for any product candidate for which we are seeking FDA approval. Additionally, these third parties and our manufacturing
facility must undergo a pre-approval inspection before we can obtain marketing authorization for any of our product candidates. Even after a manufacturer has been qualified by the FDA, the manufacturer must continue to expend time, money and effort
in the area of production and quality control to ensure full compliance with GMP. Manufacturers are subject to regular, periodic inspections by the FDA following initial approval. Further, to the extent that we contract with third parties for the
manufacture of our products, our ability to control third-party compliance with FDA requirements will be limited to contractual remedies and rights of inspection.

If, as a result of these inspections, the FDA determines that the equipment, facilities, laboratories or processes do not comply with applicable FDA regulations and conditions of product approval, the FDA
may suspend the manufacturing operations. If the manufacturing operations of any of the suppliers for our product candidates are suspended, we may be unable to generate sufficient quantities of commercial or clinical supplies of product to meet
market demand, which would harm our business. In addition, if delivery of material from our suppliers were interrupted for any reason, we may be unable to ship our approved product for commercial supply or to supply our products in development for
clinical trials. Significant delays can occur if the qualification of a new supplier is required.

Any regulatory approvals that we receive for our product candidates are likely to contain
requirements for post-marketing follow-up studies, which may be costly. Product approvals, once granted, may be modified based on data from subsequent studies or commercial use. As a result, limitations on labeling indications or marketing claims,
or withdrawal from the market may be required if problems occur after commercialization.

Failure to comply with regulatory
requirements could prevent or delay marketing approval or require the expenditure of money or other resources to correct. Failure to comply with applicable requirements may also result in warning letters, fines, injunctions, civil penalties, recall
or seizure of products, total or partial suspension of production, refusal of the government to renew marketing applications and criminal prosecution, any of which could be harmful to our ability to generate revenues and our stock price.

We may develop, seek regulatory approval for and market our product candidates outside the United States, requiring a significant commitment of
resources. Failure to successfully manage our international operations could result in significant unanticipated costs and delays in regulatory approval or commercialization of our product candidates.

We may introduce certain of our product candidates in various markets outside the United States. Developing, seeking regulatory approval
for and marketing our product candidates outside the United States could impose substantial burdens on our resources and divert managements attention from domestic operations. International operations are subject to risk, including:



the difficulty of managing geographically distant operations, including recruiting and retaining qualified employees, locating adequate facilities and
establishing useful business support relationships in the local community;



compliance with varying international regulatory requirements, laws and treaties;

the fluctuation of conversion rates between foreign currencies and the U.S. dollar; and



regional and geopolitical risks.

To date, we have not filed for marketing approval for any of our product candidates outside the United States. We may not obtain foreign regulatory approvals on a timely basis, if at all. Approval by the
FDA does not ensure approval by regulatory agencies in other foreign countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in other jurisdictions,
including approval by the FDA. If we are unable to successfully manage our international operations, we may incur significant unanticipated costs and delays in regulatory approval or commercialization of our product candidates, which would impair
our ability to generate revenues.

If any products we develop are not accepted by the market or if regulatory agencies limit our
labeling indications or marketing claims, we may be unable to generate significant revenues, if any.

Even if we obtain
regulatory approval for our product candidates and are able to commercialize them, our products may not gain market acceptance among physicians, patients, health care payors and the medical community.

The degree of market acceptance of any of our approved products will depend upon a number of
factors, including:



the indication for which the product is approved and its approved labeling;



the presence of other competing approved therapies;



the potential advantages of the product over existing and future treatment methods;



the relative convenience and ease of administration of the product;



the strength of our sales, marketing and distribution support;



the price and cost-effectiveness of the product; and



sufficient third-party reimbursement.

The FDA or other regulatory agencies could limit the labeling indication for which our product candidates may be marketed or could otherwise limit marketing efforts for our products. For example, in
connection with the removal of the clinical hold on HEPLISAV in September 2009 and related discussions with the FDA, it is expected that further development of HEPLISAV in the United States initially will be limited to individuals who are less
responsive to current licensed vaccines, including adults over 40 years of age and individuals with chronic kidney disease. If we are unable to achieve approval or successfully market any of our product candidates, or marketing efforts are
restricted by regulatory limits, our ability to generate revenues could be significantly impaired.

We face uncertainty related to
coverage, pricing and reimbursement and the practices of third party payors, which may make it difficult or impossible to sell our product candidates on commercially reasonable terms.

In both domestic and foreign markets, our ability to achieve profitability will depend in part on the negotiation of a favorable price or
the availability of appropriate reimbursement from third party payors, in particular for HEPLISAV where existing products are approved for our target indications. Existing laws affecting the pricing and coverage of pharmaceuticals and other medical
products by government programs and other third party payors may change before any of our product candidates are approved for marketing. In addition, third party payors are increasingly challenging the price and cost-effectiveness of medical
products and services, and pricing and reimbursement decisions may not allow our products to compete effectively with existing or competitive products. Because we intend to offer products, if approved, that involve new technologies and new
approaches to treating disease, the willingness of third party payors to reimburse for our products is particularly uncertain. We will have to charge a price for our products that is sufficiently high to enable us to recover our considerable
investment in product development. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to achieve profitability and could harm our future prospects and reduce our stock price.

We are unable to predict what impact the Health Care and Education Reconciliation Act of 2010 or other reform legislation will have on
our business or future prospects. The uncertainty as to the nature and scope of the implementation of any proposed reforms limits our ability to forecast changes that may affect our business. In Europe, the success of our products, in particular
HEPLISAV, will depend largely on obtaining and maintaining government reimbursement because many providers in European countries are unlikely to use medical products that are not reimbursed by their governments.

A key part of our business strategy is to establish collaborative relationships to commercialize and
fund development of our product candidates. We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to develop and commercialize our products successfully, if at all.

We will need to establish collaborative relationships to obtain domestic and international sales, marketing and
distribution capabilities for our product candidates, in particular with respect to the commercialization of HEPLISAV. Failure to obtain a collaborative relationship for HEPLISAV, particularly in the European Union, may significantly impair the
potential for this product and our ability to successfully develop, manufacture and commercialize HEPLISAV as a product candidate. We also will need to enter into collaborative relationships to provide funding to support our other research and
development programs. The process of establishing and maintaining collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:



our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, manufacturing issues, a change in
business strategy, a change of control or other reasons;



our shortage of capital resources may impact the willingness of companies to collaborate with us;



our contracts for collaborative arrangements are terminable at will on written notice and may otherwise expire or terminate and we may not have
alternative funding available;



our partners may choose to pursue alternative technologies, including those of our competitors;



we may have disputes with a partner that could lead to litigation or arbitration;



we have limited control over the decisions of our partners and they may change the priority of our programs in a manner that would result in
termination of the agreement or add significant delay in the partnered program;



our ability to generate future event payments and royalties from our partners depends upon the abilities of our partners to establish the safety and
efficacy of our drug candidates, obtain regulatory approvals, successfully manufacture, and achieve market acceptance of products developed from our drug candidates;



we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may utilize our
proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;

our partners may not comply with applicable government regulatory requirements.

If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our research, clinical development,
manufacturing, or commercialization efforts related to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of our
collaborator. If we are unable to establish and maintain collaborative relationships on acceptable terms or to successfully transition terminated collaborative agreements, we may have to delay or discontinue further development of one or more of our
product candidates, undertake development and commercialization activities at our own expense or find alternative sources of capital.

The financial terms of future collaborative licensing or financing arrangements could result in dilution of our share value.

Funding from collaboration partners and other parties may in the future involve issuance of our equity securities. Because we do not
currently have any such arrangements, we cannot be certain how the terms under

which such shares are issued will be determined or when such determinations will be made. The current market for financing or collaborative arrangements often involves the issuance of warrants as
additional consideration in establishing the purchase price of the equity securities issued. Any such issuance could result in dilution in the value of our issued and outstanding shares.

Many of our competitors have greater financial resources and expertise than we do. If we are unable to successfully compete with existing or potential competitors despite these disadvantages we may
be unable to generate revenues and our business will be harmed.

We compete with pharmaceutical companies,
biotechnology companies, academic institutions and research organizations, in developing therapies to prevent or treat infectious and inflammatory diseases. Competitors may develop more effective, more affordable or more convenient products or may
achieve earlier patent protection or commercialization of their products. These competitive products may render our product candidates obsolete or limit our ability to generate revenues from our product candidates. Many of the companies developing
competing technologies and products have significantly greater financial resources and expertise in research and development, general and administrative support, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and
marketing than we do.

Existing and potential competitors may also compete with us for qualified scientific and management
personnel, as well as for technology that would be advantageous to our business. Our success in developing marketable products and achieving a competitive position will depend, in part, on our ability to attract and retain qualified scientific,
manufacturing, sales, marketing, general and administrative and management personnel. If we do not succeed in attracting new personnel and retaining and motivating existing personnel, our operations may suffer and we may be unable to implement our
current initiatives. If we are unable to compete successfully, we may not be able to obtain financing, enter into collaborative arrangements, sell our product candidates or generate revenues.

The loss of key personnel, including our Chief Executive Officer or our President, could delay or prevent achieving our objectives.

Our research, product development and business efforts could be adversely affected by the loss of one or more key members of our
scientific or management staff, including our Chief Executive Officer, Dr. Dino Dina, or our President, Dr. J. Tyler Martin. We currently have no key person insurance on any of our employees.

We face product liability exposure, which, if not covered by insurance, could result in significant financial liability.

While we have not experienced any product liability claims to date, the use of any of our product candidates in clinical trials and the
sale of any approved products will subject us to potential product liability claims and may raise questions about a products safety and efficacy. As a result, we could experience a delay in our ability to commercialize one or more of our
product candidates or reduced sales of any approved product candidates. In addition, a product liability claim may exceed the limits of our insurance policies and exhaust our internal resources. We have obtained limited clinical trial liability and
umbrella insurance coverage for our clinical trials. This coverage may not be adequate or may not continue to be available in sufficient amounts, at an acceptable cost or at all. We also may not be able to obtain commercially reasonable product
liability insurance for any product approved for marketing in the future. A product liability claim, product recalls or other claims, as well as any claims for uninsured liabilities or in excess of insured liabilities, would divert our
managements attention from our business and could result in significant financial liability.

We use hazardous materials in our business. Any claims or liabilities relating to improper handling,
storage or disposal of these materials could be time consuming and costly to resolve.

Our research and product
development activities involve the controlled storage, use and disposal of hazardous and radioactive materials and biological waste. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling
and disposal of these materials and certain waste products. We believe we are currently in compliance with all government permits that are required for the storage, use and disposal of these materials. However, we cannot eliminate the risk of
accidental contamination or injury to persons or property from these materials. In the event of an accident related to hazardous materials, we could be held liable for damages, cleanup costs or penalized with fines, and this liability could exceed
the limits of our insurance policies and exhaust our internal resources. We may have to incur significant costs to comply with future environmental laws and regulations.

Risks Related to our Intellectual Property

We rely on licenses to intellectual
property from third parties. Impairment of these licenses or our inability to maintain them would severely harm our business.

Our current research and development efforts depend upon our license arrangements for intellectual property owned by third parties. Our dependence on these licenses subjects us to numerous risks, such as
disputes regarding the use of the licensed intellectual property and the creation and ownership of new discoveries under such license agreements. In addition, these license arrangements require us to make timely payments in order to maintain our
licenses and typically contain diligence or milestone-based termination provisions. Our failure to meet any obligations pursuant to these agreements could allow our licensors to terminate our agreements or undertake other remedies such as converting
exclusive to non-exclusive licenses if we are not able to cure or obtain waivers for such failures or amend such agreements on terms acceptable to us. In addition, our license agreements may be terminated or may expire by their terms, and we may not
be able to maintain the exclusivity of these licenses. If we cannot obtain and maintain licenses that are advantageous or necessary to the development or the commercialization of our product candidates, we may be required to expend significant time
and resources to develop or license similar technology or to find other alternatives to maintaining the competitive position of our products. If such alternatives are not available to us in a timely manner or on acceptable terms, we may be unable to
continue development or commercialize our product candidates. In addition, we must make timely payments or meet diligence obligations in order to maintain any such licenses in effect. In the absence of a current license, we may be required to
redesign our technology so it does not infringe a third partys patents, which may not be possible or could require substantial funds and time.

If third parties successfully assert that we have infringed their patents and proprietary rights or challenge our patents and proprietary rights, we may become involved in intellectual property
disputes and litigation that would be costly, time consuming, and delay or prevent development or commercialization of our product candidates.

We may be exposed to future litigation by third parties based on claims that our product candidates or proprietary technologies infringe their intellectual property rights, or we may be required to enter
into litigation to enforce patents issued or licensed to us or to determine the ownership, scope or validity of our or another partys proprietary rights, including a challenge as to the validity of our issued and pending claims. We are
involved in various interference and other administrative proceedings related to our intellectual property which has caused us to incur certain legal expenses. If we become involved in any litigation and/or other significant interference proceedings
related to our intellectual property or the intellectual property of others, we will incur substantial additional expenses and it will divert the efforts of our technical and management personnel.

Two of our potential competitors, Merck and GSK, are exclusive licensees of broad patents covering hepatitis B surface antigen, a
component of HEPLISAV. In addition, the Institut Pasteur also owns or has exclusive licenses to patents covering hepatitis B surface antigen. While some of these patents have expired or

will soon expire outside the United States, they remain in force in the United States. To the extent we are able to commercialize HEPLISAV in the United States while these patents remain in
force, Merck, GSK or the Institut Pasteur may bring claims against us.

If we or our collaborators are unsuccessful in
defending or prosecuting our issued and pending claims or in defending potential claims against our products, for example, as may arise in the commercialization of HEPLISAV or any similar product candidate, we or our collaborator could be required
to pay substantial damages or be unable to commercialize our product candidates or use our proprietary technologies without a license from such third party. A license may require the payment of substantial fees or royalties, require a grant of a
cross-license to our technology or may not be available on acceptable terms, if at all. Any of these outcomes could require us to change our business strategy and could materially impact our business and operations.

One of our potential competitors, Pfizer Inc., has issued patent claims, as well as patent claims pending with the U.S. Patent and
Trademark Office and foreign patent offices, that may be asserted against our ISS products. We may need to obtain a license to one or more of these patent claims held by Pfizer by paying fees or royalties or offering rights to our own proprietary
technologies in order to commercialize one or more of our formulations of ISS in other than with respect to HEPLISAV, for which we have a license. A license for other uses may not be available to us on acceptable terms, if at all, which could
preclude or limit our ability to commercialize our products.

If the combination of patents, trade secrets and contractual provisions
that we rely on to protect our intellectual property is inadequate, the value of our product candidates will decrease.

Our success depends on our ability to:



obtain and protect commercially valuable patents or the rights to patents both domestically and abroad;

We will be able to protect our proprietary rights from unauthorized use only to the extent that these rights are covered by valid and
enforceable patents or are effectively maintained as trade secrets. We try to protect our proprietary rights by filing and prosecuting U.S. and foreign patent applications. However, in certain cases such protection may be limited, depending in part
on existing patents held by third parties, which may only allow us to obtain relatively narrow patent protection. In the United States, legal standards relating to the validity and scope of patent claims in the biopharmaceutical field can be highly
uncertain, are still evolving and involve complex legal and factual questions for which important legal principles remain unresolved.

The biopharmaceutical patent environment outside the United States is even more uncertain. We may be particularly affected by this uncertainty since several of our product candidates may initially address
market opportunities outside the United States, where we may only be able to obtain limited patent protection.

The risks and
uncertainties that we face with respect to our patents and other proprietary rights include the following:



we may not receive an issued patent for any of our patent applications or for any patent applications that we have exclusively
licensed;



the pending patent applications we have filed or to which we have exclusive rights may take longer than we expect to result in issued patents;



the claims of any patents that are issued may not provide meaningful protection or may not be valid or enforceable;



we might not be able to develop additional proprietary technologies that are patentable;

the patents licensed or issued to us or our collaborators may not provide a competitive advantage;



patents issued to other parties may limit our intellectual property protection or harm our ability to do business;



other parties may independently develop similar or alternative technologies or duplicate our technologies and commercialize discoveries that we attempt
to patent; and



other parties may design around technologies we have licensed, patented or developed.

We also rely on trade secret protection and confidentiality agreements to protect our interests in proprietary know-how that is not
patentable and for processes for which patents are difficult to enforce. We cannot be certain that we will be able to protect our trade secrets adequately. Any disclosure of confidential data in the public domain or to third parties could allow our
competitors to learn our trade secrets. If we are unable to adequately obtain or enforce proprietary rights we may be unable to commercialize our products, enter into collaborations, generate revenues or maintain any advantage we may have with
respect to existing or potential competitors.

Risks Related to an Investment in our Common Stock

Our stock price is subject to volatility, and your investment may suffer a decline in value.

The market prices for securities of biopharmaceutical companies have in the past been, and are likely to continue in the future to be,
very volatile. The market price of our common stock is subject to substantial volatility depending upon many factors, many of which are beyond our control, including:



progress or results of any of our clinical trials or regulatory efforts, in particular any announcements regarding the progress or results of our
planned trials and communications from the FDA or other regulatory agencies;



our ability to establish and maintain collaborations for the development and commercialization of our product candidates;



our ability to raise additional capital to fund our operations;



technological innovations, new commercial products or drug discovery efforts and preclinical and clinical activities by us or our competitors;



changes in our intellectual property portfolio or developments or disputes concerning the proprietary rights of our products or product candidates;

our ability to maintain continued listing on the NASDAQ markets or similar exchanges; and



the volume of trading in our common stock.

One or more of these factors could cause a substantial decline in the price of our common stock. In addition, securities class action litigation has often been brought against a company following a
decline in the market price of its securities. This risk may be particularly relevant for us because we have experienced greater than average stock price volatility. We may in the future be the target of such litigation. Securities litigation could
result in substantial costs, and divert managements attention and resources, which could harm our business, operating results and financial condition.

The anti-takeover provisions of our certificate of incorporation, bylaws, Delaware law and our share
purchase rights plan may prevent or frustrate a change in control, even if an acquisition would be beneficial to our stockholders, which could affect our stock price adversely and prevent attempts by our stockholders to replace or remove our current
management.

Provisions of our certificate of incorporation and bylaws may delay or prevent a change in control,
discourage bids at a premium over the market price of our common stock and adversely affect the market price of our common stock and the voting or other rights of the holders of our common stock. These provisions include:



authorizing our Board of Directors to issue additional preferred stock with voting rights to be determined by the Board of Directors;



limiting the persons who can call special meetings of stockholders;



prohibiting stockholder actions by written consent;



creating a classified board of directors pursuant to which our directors are elected for staggered three year terms;



providing that a supermajority vote of our stockholders is required for amendment to certain provisions of our certificate of incorporation and bylaws;
and



establishing advance notice requirements for nominations for election to our Board of Directors or for proposing matters that can be acted on by
stockholders at stockholder meetings.

Our share purchase rights plan may have certain anti-takeover
effects. Specifically, the rights issued pursuant to the plan will cause substantial dilution to a person or group that attempts to acquire the Company on terms not approved by the Companys Board of Directors. Although the rights should not
interfere with any merger or other business combination approved by the Board of Directors since the rights issued may be amended to permit such acquisition or redeemed by the Company at $0.001 per right prior to the earliest of (i) the time
that a person or group has acquired beneficial ownership of 20% or more of the Common Shares or (ii) the final expiration date of the rights, the effect of the rights plan may deter a potential acquisition of the Company. In addition, we
remain subject to the provisions of the Delaware corporation law that, in general, prohibit any business combination with a beneficial owner of 15% or more of our common stock for three years unless the holders acquisition of our stock was
approved in advance by our Board of Directors.

We will continue to incur increased costs and demands upon management as a result of
complying with the laws and regulations affecting public companies, which could affect our operating results.

As a
public company, we will continue to incur legal, accounting and other expenses associated with reporting requirements and corporate governance requirements, including requirements under the Sarbanes-Oxley Act of 2002, the Dodd-Frank Act of 2010, as
well as new rules implemented by the Securities and Exchange Commission and the NASDAQ Stock Market LLC. We may need to continue to implement additional financial and accounting systems, procedures and controls in order to accommodate changes in our
business and organization and to comply with new reporting requirements. There can be no assurance that we will be able to maintain a favorable assessment as to the adequacy of our internal control over financial reporting. If we are unable to reach
an unqualified assessment, or our independent registered public accounting firm is unable to issue an unqualified attestation as to the effectiveness of our internal control over financial reporting as of the end of our fiscal year, investors could
lose confidence in the reliability of our financial reporting which could harm our business and could impact the price of our common stock.

Future sales of our common stock or the perception that such sales may occur in the public market
could cause our stock price to fall.

Sales of a substantial number of shares of our common stock in the public market,
or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. As of December 31, 2010, we had 115,611,069
shares of common stock outstanding, all of which shares were eligible for sale in the public market, subject in some cases to the volume limitations and manner of sale requirements under Rule 144.

We also have filed registration statements on Form S-3 under the Securities Act of 1933, as amended, to register the shares of our common
stock reserved for issuance under the Purchase Agreement, the warrants issued as part of our public offering closed in April 2010, the warrants issued to Symphony Dynamo Holdings LLC (Holdings) in connection with our acquisition of SDI
in December 2009, and warrants issued to Deerfield Management in connection with the July 2007 Loan Agreement.

In addition,
we have filed registration statements on Form S-8 under the Securities Act of 1933, as amended, to register the shares of our common stock reserved for issuance under our stock option plans, and intend to file additional registration statements on
Form S-8 to register the shares automatically added each year to the share reserves under these plans.

Symphony Capital Partners, L.P.
and Symphony Strategic Partners, LLC collectively control a substantial percentage of the voting power of our outstanding common stock as well as $15 million of our debt.

Symphony Capital Partners, L.P. and Symphony Strategic Partners, LLC (collectively, Symphony) currently collectively control
approximately 9,031,431 shares of our common stock and warrants to purchase approximately 4,515,717 shares of our common stock. Based on the number of shares of our common stock that are outstanding as of December 31, 2010, Symphony owns
approximately 8% of our total outstanding shares of our common stock. If Symphony exercises all of the warrants held by it and assuming no other issuances of our common stock, Symphony would own approximately 11% of our total outstanding shares of
common stock. In addition, Holdings, an affiliate of Symphony, holds a promissory note in the principal amount of $15 million, which may be satisfied in cash, Dynavax common stock or a combination of cash and Dynavax common stock, at our election.
Finally, under the terms of the Standstill and Corporate Governance Letter Agreement we entered into with Holdings on December 30, 2009, for as long as Holdings and its affiliates, which include Symphony, beneficially own 10% or more of our
outstanding common stock, we agreed to use our commercially reasonable efforts to cause to be elected and remain as directors on our Board of Directors one individual designated by Holdings and a second individual who shall be an independent third
party designated by Holdings and reasonably acceptable to us. Holdings designated Mark Kessel, a partner of Symphony Capital LLC, as its designee and Mr. Kessel has been appointed to our Board of Directors. On July 22, 2010, the Board of
Directors nominated Daniel L. Kisner, M.D. to the Board of Directors as the independent third party designee. As a result, Symphony, Holdings and their affiliates will be able to exercise substantial influence over the direction of the Company.

ITEM 1B.

UNRESOLVED STAFF COMMENTS

None.

ITEM 2.

PROPERTIES

As of
December 31, 2010, we lease approximately 44,000 square feet of laboratory and office space in Berkeley, California (the Berkeley Lease) under agreements expiring in September 2017. Additionally, approximately 3,000 square feet of the leased
premises under the Berkeley Lease is subleased through February 2011. We also lease approximately 5,600 square meters of laboratory and office space in Düsseldorf, Germany under lease agreements expiring in March 2023.

From
time to time in the ordinary course of business, we receive claims or allegations regarding various matters, including employment, vendor and other similar situations in the conduct of our operations. We do not believe any of the current claims or
allegations are material to our current business or operations.

MARKET FOR THE REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information and Holders

Our common stock is traded on the NASDAQ Capital Market under the symbol DVAX. Public trading of our common stock commenced on February 19, 2004. The following table sets forth for the
periods indicated the high and low sale prices per share of our common stock.

Common Stock
Price

High

Low

2010

First Quarter

$

1.83

$

1.19

Second Quarter

$

2.08

$

1.28

Third Quarter

$

2.34

$

1.58

Fourth Quarter

$

3.24

$

1.75

2009

First Quarter

$

1.04

$

0.50

Second Quarter

$

2.19

$

0.64

Third Quarter

$

3.35

$

1.15

Fourth Quarter

$

1.94

$

1.11

As of March 8,
2011, there were approximately 180 holders of record of our common stock, as shown on the records of our transfer agent. We believe that our stockholders exceed 300 as the number of record holders does not include shares held in street
name through brokers.

Dividends

We have never paid any cash dividends on our common stock. We currently expect to retain future earnings, if any, for use in the operation and expansion of our business and do not anticipate paying any
cash dividends in the foreseeable future.

The following selected financial data should be read in conjunction with Managements Discussion and Analysis of Financial
Condition and Results of Operations, and with the Consolidated Financial Statements and Notes thereto which are included elsewhere in this Form 10-K. The Consolidated Statements of Operations Data for the years ended December 31, 2010, 2009 and
2008 and the Consolidated Balance Sheets Data as of December 31, 2010 and 2009 are derived from the audited Consolidated Financial Statements included elsewhere in this Form 10-K. The Consolidated Statements of Operations Data for the years
ended December 31, 2007 and 2006 and the Consolidated Balance Sheets Data as of December 31, 2008, 2007 and 2006 are derived from Consolidated Financial Statements that are not included in this Form 10-K. Historical results are not
necessarily indicative of results to be anticipated in the future.

Years Ended December 31,

2010

2009

2008

2007

2006

(In thousands, except per share data)

Consolidated Statements of Operations Data:

Total revenues

$

23,950

$

40,318

$

37,094

$

14,093

$

4,847

Operating expenses:

Research and development

53,680

38,708

44,771

65,888

50,116

General and administrative

16,879

15,745

15,463

18,293

14,836

Acquired in-process research and development
(1)









4,180

Amortization of intangible assets

980

980

980

1,004

698

Total operating expenses

71,539

55,433

61,214

85,185

69,830

Loss from operations

(47,589

)

(15,115

)

(24,120

)

(71,092

)

(64,983

)

Interest income

85

178

1,631

3,965

3,187

Interest expense

(1,654

)

(124

)

(9,157

)

(1,719

)

(99

)

Other income (expense)
(2)

(8,150

)

(66

)

110

200

100

Loan forgiveness
(3)





5,000





Net loss.

(57,308

)

(15,127

)

(26,536

)

(68,646

)

(61,795

)

Consideration paid in excess of carrying value of the noncontrolling interest in SDI
(4)

Basic and diluted net loss per share attributable to Dynavax common stockholders

$

(0.69

)

$

(0.76

)

$

(0.52

)

$

(1.51

)

$

(1.61

)

Shares used to compute basic and diluted net loss per share attributable to Dynavax common stockholders

82,463

40,350

39,819

39,746

32,339

(1)

Represents acquired in-process research and development. This amount relates to the Rhein Biotech GmbH acquisition in April 2006.

(2)

Includes the impact of the anti-dilution provision associate with the common stock and warrants issued to Symphony and the change in fair value of the long-term
contingent and warrant liabilities to Symphony for the year ended December 31, 2010. See Note 8 to the Consolidated Financial Statements.

(3)

Represents a $5.0 million portion of the loan from Deerfield that was forgiven upon termination of the loan agreement. See Note 9 to the Consolidated Financial
Statements.

(4)

Represents the consideration paid in excess of the carrying value of the noncontrolling interest in SDI and is treated as a deemed dividend for purposes of reporting
earnings per share, increasing loss per share for the year ended December 31, 2009. See Note 8 to the Consolidated Financial Statements.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following Managements Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking
statements that involve a number of risks and uncertainties. Our actual results could differ materially from those indicated by forward-looking statements as a result of various factors, including but not limited to, the period for which we estimate
our cash resources are sufficient, the availability of additional funds, as well as those set forth under Risk Factors and those that may be identified from time to time in our reports and registration statements filed with the
Securities and Exchange Commission.

The following discussion and analysis is intended to provide an investor with a
narrative of our financial results and an evaluation of our financial condition and results of operations. The discussion should be read in conjunction with Item 6Selected Financial Data and the Consolidated Financial Statements
and the related notes thereto set forth in Item 8Financial Statements and Supplementary Data.

Overview

Dynavax Technologies Corporation (Dynavax or the Company), a clinical-stage biopharmaceutical
company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Our lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide rapid and superior protection
with fewer doses than current licensed vaccines.

The accompanying discussion and analysis of our financial condition and
results of operations are based upon our consolidated financial statements and the related disclosures, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires
us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the balance sheet dates and the reported amounts of revenues and expenses for the
periods presented. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, research and development activities, stock-based compensation, asset impairment, contingencies, and the valuation of certain
liabilities. We base our estimates on historical experience and on

various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities
that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in Note 2 to the consolidated financial statements, we believe the following critical accounting policies reflect the more significant
judgments and estimates used in the preparation of our financial statements.

Revenue Recognition

Our revenues are derived from collaborative and service agreements as well as grants. Collaborative agreements may include upfront license
payments, cost reimbursement for the performance of research and development, milestone payments, contract manufacturing services, and royalty fees. We recognize revenue when there is persuasive evidence that an arrangement exists, delivery has
occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Our revenue arrangements that contain multiple elements are evaluated under established accounting guidance. The different elements
of the revenue arrangement are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer and whether there is objective and reliable evidence of the fair
value of the undelivered items. The consideration we receive is allocated among the separate units based on their respective fair values, and the applicable revenue recognition criteria are applied to each of the separate units. For agreements which
do not meet the criteria of separate units of accounting under established accounting guidance, the total consideration received is grouped as one unit and the applicable revenue recognition methodology is applied to the single unit. Advance
payments received in excess of amounts earned are classified as deferred revenue until earned.

Revenue from non-refundable
upfront license fees and other payments under collaboration agreements where we have continuing performance obligations is deferred and recognized as performance occurs. Revenue is recognized on a ratable basis, unless we determine that another
methodology is more appropriate, through the date at which our performance obligations are completed. We recognize cost reimbursement revenue under collaborative agreements as the related research and development costs are incurred, as provided for
under the terms of these agreements.

Revenue from milestones that are contingent upon the achievement of substantive at-risk
performance criteria is recognized in full upon achievement of those milestone events in accordance with the terms of the agreement and assuming all other revenue recognition criteria have been met. All revenue recognized to date under our
collaborative agreements has been nonrefundable.

Revenues from the manufacturing and sale of vaccine and other materials are
recognized upon meeting the criteria for substantial performance and acceptance by the customer.

Revenue from royalty
payments is contingent on future sales activities by our licensees. As a result, we recognize royalty revenue when reported by our licensees and when collection is reasonably assured.

Revenue from government and private agency grants are recognized as the related research expenses are incurred and to the extent that
funding is approved. Additionally, we recognize revenue based on the facilities and administrative cost rate reimbursable per the terms of the grant awards.

Research and Development Expenses and Accruals

Research and
development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services, and non-cash stock-based
compensation. Research and development costs are expensed as incurred. For agreements with third parties for clinical trials, manufacturing and process development, research

and other consulting activities entered into prior to January 1, 2008, costs were expensed upon the earlier of when non-refundable amounts were due or as services were performed. Amounts due
under such arrangements may be either fixed fee or fee for service, and may include upfront payments, monthly payments, and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements
entered into after January 1, 2008 are capitalized and expensed as the related goods are delivered or services are performed.

Our accruals for clinical trials are based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. We contract
with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment
flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, completion of portions of the clinical trial, or similar conditions. We may terminate these contracts
upon written notice and we are generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances we may be further responsible for termination fees and penalties.

Stock-Based Compensation

Determining the appropriate fair value model and calculating the fair value of stock-based awards at the grant date requires judgment and estimates. The fair value of each option is amortized on a
straight-line basis over the options vesting period, assuming an annual forfeiture rate of 15% for both the executive level and non-executive level employee groups, and is estimated on the date of grant using the Black-Scholes option valuation
model, which requires the input of highly subjective assumptions, including the expected life of the option and expected stock price volatility. The expected life of options granted is estimated based on historical option exercise and employee
termination data. Executive level and non-executive level employees were grouped and considered separately for valuation purposes. In 2008, based on employee termination data we adjusted the expected life of the options for both groups of employees
to 4 years, which remains consistent for fiscal years ended December 31, 2009 and 2010. Expected volatility is based on historical volatility of our stock and comparable peer data over the life of the options granted to executive and
non-executive level employees.

Goodwill and Other Intangible Assets

Goodwill is recorded as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their
estimated fair value, by applying the acquisition method of accounting. The ongoing evaluation for impairment of goodwill requires significant management estimates and judgment. The Company operates in one segment and we evaluate goodwill for
impairment on an annual basis and on an interim basis if events or changes in circumstances between annual impairment tests indicate that the asset might be impaired.

Impairment of Long-lived Assets

Long-lived assets to be held and
used, including property and equipment and identified intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Factors we consider important
that could indicate the need for an impairment review include the following:

a current expectation that, more likely than not, a long lived asset (asset group) will be sold or otherwise disposed of significantly before the end
of its previously estimated useful life; and



our market capitalization relative to net book value.

Determination of recoverability is based on an estimate of undiscounted cash flows resulting from the use of the asset and its eventual disposition. Measurement of impairment charges for long-lived assets
that management expects to hold and use are based on the fair value of such assets.

Consolidation of Variable Interest
Entities

Arrangements that are not controlled through voting or similar rights are accounted for as variable interest
entities (VIEs). An enterprise is required to consolidate a VIE if it is the primary beneficiary of the VIE. The enterprise that is deemed to absorb a majority of the expected losses or receive a majority of expected residual returns of
the VIE is considered the primary beneficiary.

We have concluded that under certain circumstances when we enter into
agreements that contain an option to purchase assets or equity securities from an entity, or enter into an arrangement with a financial partner for the formation of joint ventures which engage in research and development projects, a VIE may be
created. For each VIE created, we compute expected losses and residual returns based on the probability of future cash flows. If we are determined to be the primary beneficiary of the VIE, the assets, liabilities and operations of the VIE will be
consolidated with our financial statements. Prior to the acquisition of all of the outstanding equity of SDI pursuant to the Amended Purchase Option on December 30, 2009, our consolidated financial statements include the accounts of SDI, a VIE,
of which we were the primary beneficiary.

Results of Operations

Revenues

Revenues consist of amounts earned from collaborations, grants, services and license fees. Collaboration revenue includes revenue recognized under our collaboration agreements. Grant revenue includes
amounts earned under government and private agency grants. Services and license fees include research and development and contract manufacturing services, license fees and royalty payments.

The following is a summary of our revenues for the years ended December 31, 2010, 2009 and 2008 (in thousands, except for
percentages):

Years Ended December 31,

Increase
(Decrease) from
2009 to 2010

Increase
(Decrease)
from
2008 to 2009

Revenues:

2010

2009

2008

$

%

$

%

Collaboration revenue

$

19,535

$

35,534

$

31,666

$

(15,999

)

(45

)%

$

3,868

12

%

Grant revenue

3,940

3,477

2,999

463

13

%

478

16

%

Services and license revenue

475

1,307

2,429

(832

)

(64

)%

(1,122

)

(46

)%

Total revenues

$

23,950

$

40,318

$

37,094

$

(16,368

)

(41

)%

$

3,224

9

%

Total revenues for the year ended December 31, 2010 decreased by $16.4 million, or 41%, as
compared to 2009 primarily due to the reduction in collaboration revenue following the termination of our collaboration with Merck. Collaboration revenue for the year ended December 31, 2010 included recognition of the $10.0 million upfront
payment received from AstraZeneca in 2006 following the recent amendment of our collaboration agreement, $4.1 million of other revenue related to our collaboration with AstraZeneca, and a $4.0 million payment from Merck in satisfaction of its
obligations. Grant revenue for the year ended December 31, 2010 increased from the same period in 2009 primarily due to the increase in revenue recognized for the NIAID

contract. Services and license revenue for the year ended December 31, 2010 decreased as compared to 2009 as a result of a decline in royalty revenue and manufacturing services from Rhein
Biotech GmbH (Rhein or Dynavax Europe).

Total revenues for the year ended December 31, 2009
increased by $3.2 million, or 9%, as compared to 2008 primarily resulting from higher collaboration revenue. Collaboration revenue for the year ended December 31, 2009 included recognition of $28.5 million of the upfront payment from the Merck
collaboration following its termination, and $5.1 million of other revenue related to our collaboration with AstraZeneca. Grant revenue for the year ended December 31, 2009 increased from the same period in 2008 due primarily to revenues earned
from the NIAID contract. Services and license revenue for the year ended December 31, 2009 decreased as compared to 2008 as a result of a decline in research and development services provided by Rhein.

The following is a summary of our research and development expense (in thousands, except percentages):

Years Ended December 31,

Increase
(Decrease) from
2009 to 2010

Increase
(Decrease)
from
2008 to 2009

Research and Development:

2010

2009

2008

$

%

$

%

Compensation and related personnel costs

$

14,867

$

15,601

$

18,020

$

(734

)

(5

)%

$

(2,419

)

(13

)%

Outside services

31,372

14,985

18,477

16,387

109

%

(3,492

)

(19

)%

Facility costs

6,809

6,983

6,871

(174

)

(2

)%

112

2

%

Non-cash stock-based compensation

632

1,139

1,403

(507

)

(45

)%

(264

)

(19

)%

Total research and development

$

53,680

$

38,708

$

44,771

$

14,972

39

%

$

(6,063

)

(14

)%

Research and development expense for the year ended December 31, 2010 increased by $15.0
million, or 39%, as compared to 2009. The increase in outside services during 2010 is primarily due to continued clinical and manufacturing activities associated with HEPLISAV. The increase in outside services expense was partially offset by a
decrease in compensation and related personnel costs and stock-based compensation over the same period primarily due to the decline in employee headcount.

Research and development expenses for the year ended December 31, 2009 decreased by $6.1 million, or 14%, as compared to 2008. The decrease in outside services during 2009 resulted from reduced
clinical development costs for HEPLISAV during the period in which HEPLISAV was on clinical hold and the discontinuation of clinical development for the TOLAMBA ragweed allergy program. Compensation and related personnel costs decreased in 2009 due
to a reduction in the number of employees engaged in research and development.

We expect research and development expenses in
2011 to be consistent with 2010.

General and administrative expenses consist primarily of compensation and related personnel costs; outside services such as accounting,
consulting, business development, investor relations and insurance; legal costs that include corporate and patent expenses; allocated facility costs; and non-cash stock-based compensation. The following is a summary of our general and administrative
expenses (in thousands, except for percentages):

Years Ended December 31,

Increase
(Decrease) from
2009 to 2010

Increase
(Decrease) from
2008 to 2009

General and Administrative:

2010

2009

2008

$

%

$

%

Compensation and related personnel costs

$

6,318

$

5,886

$

6,810

$

432

7

%

$

(924

)

(14

)%

Outside services

4,207

4,033

4,209

174

4

%

(176

)

(4

)%

Legal costs

3,622

3,003

1,696

619

21

%

1,307

77

%

Facility costs

971

927

946

29

3

%

(19

)

(2

)%

Non-cash stock-based compensation

1,761

1,896

1,802

(135

)

(7

)%

94

5

%

Total general and administrative

$

16,879

$

15,745

$

15,463

$

1,134

7

%

$

282

2

%

General and administrative expenses for the year ended December 31, 2010 increased by $1.1
million, or 7%, compared to the same period in 2009. The increase is primarily due to an increase in legal costs related to patent activities, as well as personnel costs for travel and recruitment to support HEPLISAV development and other business
efforts.

General and administrative expenses for the year ended December 31, 2009 increased by $0.3 million, or 2%,
compared to the same period in 2008. The increase is primarily due to an increase in legal costs related to patent activities, partially offset by a decrease in compensation and related personnel costs resulting from a reduction in the number of
administrative employees providing organizational support.

We expect general and administrative expenses in 2011 to be
consistent with 2010.

Amortization of Intangible Assets

Intangible assets consist primarily of the manufacturing process and customer relationships resulting from our April 2006 acquisition of
Rhein and are being amortized over five years from the date of acquisition. Amortization of intangible assets was $1.0 million for each of the three years ended December 31, 2010, 2009 and 2008.

Interest Income, Interest Expense, Other Income (Expense) and Loan Forgiveness

Interest income is reported net of amortization of premiums and discounts on marketable securities and realized gains and losses on
investments. Other income includes gains and losses on foreign currency transactions, gains and losses on disposals of property and equipment and the change in fair value of financial assets and liabilities such as the warrants and contingent
consideration liabilities assumed in connection with the acquisition of SDI on December 30, 2009. Interest expense includes amortization of deferred transaction costs and commitment fees related to the Deerfield Loan Agreement dated
July 18, 2007 (the Loan Agreement) and accretion of the note payable issued to Holdings in connection with our acquisition of SDI. The following is a summary of our interest income, interest expense, other income (expense) and loan
forgiveness (in thousands, except for percentages):

Interest income for the year ended December 31, 2010 decreased by $0.1 million, or 52%,
compared to the same period in 2009 due primarily to lower returns on our investment portfolio resulting from market conditions. Interest income for the year ended December 31, 2009 decreased by $1.5 million, or 89%, compared to the same period
in 2008 due primarily to lower investment balances and the decline in returns on our investment portfolio resulting from market conditions.

Interest expense for the year ended December 31, 2010 increased by $1.5 million compared to the same period in 2009 due primarily to interest from the accretion of the note payable to Holdings.
Interest expense for the year ended December 31, 2009 decreased by $9.0 million, or 99%, compared to the same period in 2008 due primarily to the termination of the Loan Agreement with Deerfield in August 2008.

Other income (expense) for the year ended December 31, 2010 primarily includes the impact of the anti-dilution provision associated
with the common stock and warrants issued to Symphony in April 2010, the warrant liability remeasured through June 30, 2010, which resulted in non-operating expense of $11.0 million, partially offset by a gain of $2.2 million for the change in
fair value of the long-term contingent liability to Symphony. Following the expiration date of Symphonys anti-dilution protection of June 30, 2010, the value of the April 2010 Warrants were reclassified in stockholders equity in the
consolidated balance sheet. Additionally, in 2010 we received $0.7 million in grants under The Patient Protection and Affordable Care Act of 2010, awarded to us to cover research and development costs from 2009 and 2010 for our qualified therapeutic
discovery projects including HEPLISAV.

Loan forgiveness in 2008 represents a $5.0 million portion of the loan from Deerfield
that was forgiven upon termination of the loan agreement.

Pursuant to the agreements that we entered into with SDI (a VIE) in April 2006, the results of operations
of SDI have been included in our consolidated financial statements from the date of formation on April 18, 2006. We have deducted the losses attributed to the noncontrolling interest in the determination of net loss in our consolidated
statements of operations through December 30, 2009, the date we acquired all the outstanding equity of SDI. For the fiscal years ended December 31, 2010, 2009 and 2008, the losses attributable to the noncontrolling interest were zero, $4.2
million and $5.7 million, respectively.

Consideration Paid in Excess of Carrying Value of the Noncontrolling Interest
in Symphony Dynamo, Inc.

Upon closing of the acquisition of all of the outstanding equity of SDI pursuant to the
Amended Purchase Option, we recorded the acquisition as a capital transaction that did not affect our net loss. However, because the acquisition was accounted for as a capital transaction, the excess consideration transferred over the carrying value
of the noncontrolling interest in SDI was treated as a deemed dividend for purposes of reporting net loss and net loss per share attributable to us, increasing net loss and net loss per share attributable to our common stockholders by $19.7 million
or $0.76 per share for the year ended December 31, 2009.

Recent Accounting Pronouncements

Accounting Standards Update 2010-17

In March 2010, the FASB reached a consensus on Accounting Standards Update (ASU) No. 2010-17, Milestone Method of Revenue Recognition, or ASU 2010-17. ASU 2010-17 provides
guidance on applying the milestone method to milestone payments for achieving specified performance measures when those payments are related to uncertain future events. Under the consensus, entities can make an accounting policy election to
recognize arrangement consideration received for achieving specified performance measures during the period in which the milestones are achieved, provided certain criteria are met. The scope of this Issue is limited to

transactions involving research or development. This new guidance is effective for fiscal years beginning on or after June 15, 2010, and we will adopt it prospectively as of January 1,
2011 such that it will be applicable to revenue arrangements entered into or materially modified on or after that date. While we do not expect the adoption of this standard to have a material impact on our financial position and results of
operations, this standard may impact us in the event we complete future transactions or modify existing collaborative relationships.

Accounting Standards Update 2010-06

In January 2010, the FASB
issued ASU No. 2010-06, Improving Disclosures about Fair Value Measurements or ASU 2010-06, which is included in the ASC Topic 820 (Fair Value Measurements and Disclosures). ASU 2010-06 requires new disclosures on the amount and
reason for transfers in and out of Level 1 and 2 fair value measurements. ASU 2010-06 also requires disclosure of activities including purchases, sales, issuances, and settlements within the Level 3 fair value measurements and clarifies existing
disclosure requirements on levels of disaggregation and disclosures about inputs and valuation techniques. We adopted ASU 2010-06 effective January 1, 2010. The adoption of ASU 2010-06 did not have a material impact on the consolidated
financial statements of the Company.

Accounting Standards Update 2009-13

In October 2009, the FASB issued ASU No. 2009-13, Multiple-Deliverable Revenue Arrangements or ASU No. 2009-13. ASU
No. 2009-13 amends existing revenue recognition accounting pronouncements and provides accounting principles and application guidance on whether multiple deliverables exist, how an arrangement should be separated and the consideration
allocated. This guidance eliminates the requirement to establish the fair value of undelivered products and services in order to treat deliverables in an arrangement as separate units of accounting and provides for separate revenue recognition based
upon managements estimate of the relative selling price for each deliverable in an arrangement. This new guidance is effective for fiscal years beginning on or after June 15, 2010, and we will adopt it prospectively as of January 1,
2011 such that it will be applicable to revenue arrangements entered into or materially modified on or after that date. While we do not expect the adoption of this standard to have a material impact on our financial position and results of
operations, this standard may impact us in the event we complete future transactions or modify existing collaborative relationships.

Liquidity and Capital Resources

As of December 31, 2010, we had $72.2 million in cash, cash equivalents and marketable securities. Our funds are currently invested in short-term money market funds, government agency securities and
corporate obligations.

Cash used in operating activities during the year ended December 31, 2010 was $51.4 million
compared to $33.6 million for the same period in 2009. The increase in cash usage compared to the prior year was due to our net loss and changes in working capital, particularly increased spending for HEPLISAV development. Cash used in operating
activities during the year ended December 31, 2009 was $33.6 million compared to $17.0 million for the same period in 2008. The increase in cash usage over the prior year was due primarily to the decline in payments received from the
collaboration with Merck, which was terminated in December 2008 and an increase in our net loss for 2009.

Cash used in
investing activities during the year ended December 31, 2010 was $50.5 million compared to cash provided of $19.9 million for 2009. The change was primarily due to the purchase of marketable securities in 2010. Cash provided by investing
activities during the year ended December 31, 2009 was $19.9 million compared to $30.1 million for the same period in 2008. The decrease in cash provided was primarily attributed to fewer proceeds from maturities of marketable securities.

Cash provided by financing activities during the year ended December 31, 2010 was $87.6
million compared to $22.1 million for the same period in 2009. The increase was primarily attributed to the completion of public offerings in April and November 2010, which resulted in aggregated net proceeds of $87.4 million. Additionally, prior to
the termination of our equity distribution agreement with Wedbush Morgan Securities (Wedbush) on September 14, 2010, we sold 900,860 shares of common stock for net proceeds of $1.2 million during fiscal year 2010. Cash provided by
financing activities during the year ended December 31, 2009 was $22.1 million compared to $1.4 million for the same period in 2008. Cash provided by financing activities primarily included gross proceeds of $20.1 million from the acquisition
of SDI and $2.2 million from sales of our common stock under an equity distribution agreement entered into with Wedbush on August 17, 2009.

On September 20, 2010, we entered into the Purchase Agreement with Aspire Capital, which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital
is committed to purchase an aggregate of $30.0 million of shares of our common stock over the 25-month term of the Purchase Agreement. Under the Purchase Agreement, we agreed to pay Aspire Capital a commitment fee equal to 4% of $30 million in
consideration for Aspire Capitals obligation to purchase up to $30 million of our common stock. We paid this commitment fee by issuance of 600,000 shares of our common stock valued at $2.00 per share. Upon execution of the Purchase Agreement,
we sold 1,000,000 shares of our common stock to Aspire Capital at a purchase price of $2.00 per share, for an aggregate purchase price of $2 million. In October 2010, we raised approximately $1.3 million from the issuance of 750,000 shares of common
stock under the Purchase Agreement. As of December 31, 2010, we could offer and sell from time to time to Aspire Capital up to an additional $26.7 million in aggregate offering price of our common stock under the Purchase Agreement.

On November 2, 2010, we completed an underwritten public offering of 26,450,000 shares of our common stock including 3,450,000
shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters at a price to the public of $1.70 per share. The net proceeds to us from this offering were $42.0 million, after deducting underwriting
discounts and commissions and other offering expenses payable by us.

We expect to continue to spend substantial funds in
connection with development and manufacturing of our product candidates, particularly HEPLISAV; various human clinical trials for our product candidates; and protection of our intellectual property. In order to continue development of our product
candidates, particularly HEPLISAV, we will need to raise additional funds. This may occur through our Purchase Agreement with Aspire Capital, future public or private financings and/or strategic alliance and licensing arrangements. Sufficient
funding may not be available, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing shareholders. If adequate funds are not available in the future, we would need to delay, reduce the scope
of, or put on hold the HEPLISAV program or other development programs while we seek strategic alternatives.

We currently
estimate that we will have sufficient cash resources to meet our cash needs through the next twelve months based on cash and cash equivalents and marketable securities on hand at December 31, 2010, anticipated revenues from existing agreements
and the funding available to us under the Purchase Agreement with Aspire Capital. We note that our independent registered public accounting firm has included in their audit opinion for the fiscal year ended December 31, 2010, a statement with
respect to substantial doubt regarding our ability to continue as a going concern. Our consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of
assets and the satisfaction of liabilities in the normal course of business.

The following summarizes our significant contractual obligations as of December 31, 2010 and the effect those obligations are
expected to have on our liquidity and cash flow in future periods (in thousands):

We lease our facilities in Berkeley, California or the Berkeley Lease, and Düsseldorf, Germany (the
Düsseldorf Lease) under operating leases that expire in September 2017 and March 2023, respectively. In October 2010, we amended our Berkeley Lease to reduce the Companys leased premises and extend the term of the lease
through September 30, 2017. Commencing on the reduction effective date, which is no later than April 1, 2011, the monthly base rent for the Berkeley facility will be reduced proportionately by the reduction in square footage and is subject
to scheduled escalation on an annual basis thereafter. We have entered into a sublease agreement under the Berkeley Lease for a certain portion of the leased space with the total remaining scheduled payments of $10,600 due to us until February 2011.
We have also entered into two sublease agreements under the Düsseldorf Lease for certain portion of the leased space with total remaining scheduled payments of $0.2 million due to us through July 2013.

As part of the consideration we transferred to Holdings for the acquisition of SDI, we are obligated to make contingent cash payments
equal to 50% of the first $50 million from any upfront, pre-commercialization milestone or similar payments received by us from any agreement with any third party with respect to the development and/or commercialization of the cancer and hepatitis C
therapies. Using a discounted cash flow model, we estimated the fair value of the contingent liability to be $0.8 million as of December 31, 2010.

During the fourth quarter of 2004, we established a letter of credit with Silicon Valley Bank as security for our Berkeley Lease in the amount of $0.4 million. The letter of credit remained outstanding as
of December 31, 2010 and is collateralized by a certificate of deposit which has been included in restricted cash in the consolidated balance sheets as of December 31, 2010 and 2009. Under the terms of the Berkeley Lease, if the total
amount of our cash, cash equivalents and marketable securities falls below $20.0 million for a period of more than 30 consecutive days during the lease term, the amount of the required security deposit will increase to $1.1 million, until such time
as our projected cash and cash equivalents will exceed $20.0 million for the remainder of the lease term, or until our actual cash and cash equivalents remains above $20.0 million for a period of 12 consecutive months.

We established a letter of credit with Deutsche Bank as security for our Düsseldorf Lease in the amount of $0.3 million. The letter
of credit remained outstanding as of December 31, 2010 and is collateralized by a certificate of deposit which has been included in restricted cash in the consolidated balance sheets as of December 31, 2010 and 2009.

In addition to the non-cancelable commitments included above, we have entered into contractual arrangements that obligate us to make
payments to the contractual counterparties upon the occurrence of future events. In the normal course of operations, we have entered into license and other agreements and intend to continue to seek additional rights relating to compounds or
technologies in connection with our discovery, manufacturing and development programs. Under the terms of the agreements, we may be required to pay future up-front fees, milestones and royalties on net sales of products originating from the licensed
technologies. We consider these potential obligations to be contingent and have summarized all significant arrangements below.

We rely on research institutions, contract research organizations, clinical investigators
and clinical material manufacturers. As of December 31, 2010, under the terms of our agreements, we are obligated to make future payments as services are provided of approximately $10.6 million through 2013. These agreements are terminable by
us upon written notice. We are generally only liable for actual effort expended by the organizations at any point in time during the contract, subject to certain termination fees and penalties.

Under the terms of our exclusive license agreements with the Regents of the University of California, as amended, for certain technology
and related patent rights and materials, we pay annual license or maintenance fees and will be required to pay milestones and royalties on net sales of products covered by patents and patent applications originating from the licensed technologies.
Under the terms of our license agreements, we expected to pay approximately $0.8 million through 2012 related to such fees and milestone payments to the Regents.

Off-balance Sheet Arrangements

We do not have any off-balance sheet
arrangements as defined by rules enacted by the SEC and accordingly, no such arrangements are likely to have a current or future effect on our financial position. As described above, SDI is considered a VIE and is included in our financial
statements through December 30, 2009, the date we acquired all the outstanding equity in SDI. Our financing arrangement with SDI does not qualify as an off-balance sheet arrangement as defined by applicable SEC regulations.

ITEM 7A. QUANTITATIVE

AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Quantitative and Qualitative Disclosure About Market Risk

The primary
objective of our investment activities is to preserve principal while at the same time maximize the income we receive from our investments without significantly increasing risk. Some of the securities that we invest in may have market risk. This
means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, we currently maintain our portfolio of cash equivalents and investments in a variety of securities, including
money market funds, government agency securities and corporate obligations, some of which are government-secured. We do not invest in auction rate securities or securities collateralized by home mortgages, mortgage bank debt, or home equity loans.
Our investment portfolio approach has been consistent for our recent fiscal years. Because of the short-term maturities of our cash equivalents and marketable securities, we do not believe that an increase in market rates would have any significant
negative impact on the realized value of our investments.

Interest Rate Risk.
We do not use
derivative financial instruments in our investment portfolio. Due to the short duration and conservative nature of our cash equivalents and marketable securities, we do not expect any material loss with respect to our investment portfolio.

Foreign Currency Risk
. We have certain investments outside the United States for the operations
of Dynavax Europe and have some exposure to foreign exchange rate fluctuations. The cumulative translation adjustment reported in the consolidated balance sheet as of December 31, 2010 was $0.7 million primarily related to translation of
Dynavax Europe assets, liabilities and operating results from Euros to U.S. dollars. To date, the effect of our exposure to these exchange rate fluctuations has not been material, and we do not expect it to become material in the foreseeable future.
We do not hedge our foreign currency exposures and have not used derivative financial instruments for speculation or trading purposes.

The Board of Directors and Stockholders of Dynavax Technologies Corporation

We have audited the accompanying consolidated balance sheets of Dynavax Technologies Corporation as of December 31, 2010 and 2009,
and the related consolidated statements of operations, stockholders equity, and cash flows for each of the three years in the period ended December 31, 2010. These financial statements are the responsibility of the Companys
management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our
audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Dynavax Technologies Corporation at December 31, 2010 and
2009, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2010, in conformity with U.S. generally accepted accounting principles.

As discussed in Note 2 to the consolidated financial statements, Dynavax Technologies Corporations recurring losses from operations
raise substantial doubt about its ability to continue as a going concern. Managements plans as to these matters also are described in Note 2. The 2010 consolidated financial statements do not include any adjustments that might result from the
outcome of this uncertainty.

We also have audited, in accordance with the standards of the Public Company Accounting
Oversight Board (United States), Dynavax Technologies Corporations internal control over financial reporting as of December 31, 2010, based on criteria established in Internal ControlIntegrated Framework issued by the Committee of
Sponsoring Organizations of the Treadway Commission and our report dated March 11, 2011, expressed an unqualified opinion thereon.

Dynavax Technologies Corporation
(Dynavax or the Company), a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Our lead product candidate is HEPLISAV, a Phase 3
investigational adult hepatitis B vaccine designed to provide rapid and superior protection with fewer doses than current licensed vaccines.

Our pipeline of product candidates includes: HEPLISAV; clinical-stage programs for our Universal Flu vaccine and hepatitis C and hepatitis B therapies; and preclinical programs partnered with
GlaxoSmithKline (GSK) and AstraZeneca. We compete with pharmaceutical companies, biotechnology companies, academic institutions and research organizations in developing therapies to prevent or treat infectious diseases, asthma and
inflammatory and autoimmune diseases. Our product candidates are based on the use of immunostimulatory and immunoregulatory sequences. We were incorporated in California in August 1996 under the name Double Helix Corporation, and we changed our
name to Dynavax Technologies Corporation in September 1996. We reincorporated in Delaware in 2001.

Subsidiaries

In December 2009, we completed the acquisition of Symphony Dynamo, Inc. (SDI), which became a wholly-owned subsidiary (see
Note 8). In April 2006, we completed the acquisition of Rhein Biotech GmbH (Rhein), a wholly-owned subsidiary in Düsseldorf, Germany.

2. Summary of Significant Accounting Policies

Basis of
Presentation

The consolidated financial statements include our accounts and those of our wholly-owned subsidiaries. Prior
to December 30, 2009, Dynavax consolidated the financial results of SDI, as SDI was deemed a variable interest entity and we were deemed the primary beneficiary. All significant intercompany accounts and transactions have been eliminated. We
operate in one business segment, which is the discovery and development of biopharmaceutical products. In fiscal years 2010, 2009 and 2008, 98%, 97% and 93% of our revenues were earned in the United States, respectively, and the remaining revenues
were earned in Europe. As of December 31, 2010 and 2009, 41% and 43%, respectively, of our long-lived assets were located in the United States and the remaining assets were located in Europe. We have reclassified the prior year restricted cash
balance from current to long-term in order to conform to the current year presentation. The reclassification had no impact on our overall financial position or results of operations.

Liquidity and Financial Condition

We have incurred significant operating
losses and negative cash flows from operations since our inception. As of December 31, 2010, we had cash, cash equivalents and marketable securities of $72.2 million, restricted cash of $0.7 million and working capital of $59.8 million. We
currently estimate that we have sufficient cash resources to meet our anticipated cash needs through the next twelve months based on cash and cash equivalents and marketable securities on hand at December 31, 2010, anticipated revenues from
existing agreements and the funding available to us under the September 2010 Common Stock Purchase Agreement (the Purchase Agreement) with Aspire Capital Fund, LLC (Aspire Capital).

In order to continue development of our product candidates, particularly HEPLISAV, we will need to raise significant additional funds.
This may occur through our Purchase Agreement with Aspire Capital, future public or private financings and/or strategic alliance and licensing arrangements. Sufficient additional funding may not

be available on acceptable terms, or at all. Additional equity financings, if completed, could result in significant dilution or otherwise adversely affect the rights of existing shareholders. If
adequate funds are not available in the future, we would need to delay, reduce the scope of, or put on hold the HEPLISAV program or our other development programs while we seek strategic alternatives.

The accompanying financial statements have been prepared assuming we will continue to operate as a going concern, which contemplates the
realization of assets and the settlement of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets
or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern.

Use of Estimates

The
preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying
notes. Actual results may differ from these estimates.

Foreign Currency

We consider the local currency to be the functional currency for our international subsidiary. Accordingly, assets and liabilities
denominated in foreign currencies are translated into U.S. dollars using the exchange rate on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing throughout the year. Currency translation adjustments are
charged or credited to accumulated other comprehensive income (loss) in the consolidated balance sheets. For the years ended December 31, 2010, 2009 and 2008, we reported a loss of $0.7 million, a gain of $0.2 million, and a loss of $0.7
million, respectively. Gains and losses resulting from currency transactions are included in the consolidated statements of operations. We reported a $0.1 million loss resulting from currency transactions in our consolidated statement of operations
for the year ended December 31, 2010.

Cash, Cash Equivalents and Marketable Securities

We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Management
determines the appropriate classification of marketable securities at the time of purchase. We invest in short-term money market funds, government agency securities and corporate obligations, some of which are government-secured. We believe these
types of investments are subject to minimal credit and market risk. We do not invest in auction rate securities or securities collateralized by home mortgages, mortgage bank debt, or home equity loans.

We have classified our entire investment portfolio as available-for-sale. We view our available-for-sale portfolio as available for use
in current operations, and accordingly, have classified all investments as short-term. Available-for-sale securities are carried at fair value based on inputs that are observable, either directly or indirectly, such as quoted market prices for
similar securities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the securities with unrealized gains and losses included in
accumulated other comprehensive income (loss) in stockholders equity. Realized gains and losses and declines in value, if any, judged to be other than temporary on available-for-sale securities are included in interest income or expense. The
cost of securities sold is based on the specific identification method. Management assesses whether declines in the fair value of investment securities are other than temporary. In determining whether a decline is other than temporary, management
considers the following factors:



Length of time and the extent to which the market value has been less than cost;



The financial condition and near-term prospects of the issuer; and



Our intent and ability to retain our investment in the issuer for a period of time sufficient to allow for any anticipated recovery in market value.

To date, there have been no declines in fair value that have been identified as other than
temporary.

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that are subject to concentration of credit risk consist primarily of cash and cash equivalents, marketable
securities, and accounts receivable. Our policy is to invest cash in institutional money market funds and marketable securities of U.S. government and corporate issuers with high credit quality in order to limit the amount of credit exposure. We
currently maintain a portfolio of cash equivalents and investments in a variety of securities, including money market funds, government agency securities and corporate obligations, some of which are government-secured. We do not invest in auction
rate securities or securities collateralized by home mortgages, mortgage bank debt, or home equity loans. We have not experienced any losses on our cash and cash equivalents and marketable securities.

Trade accounts receivable are recorded at invoice value. We review our exposure to accounts receivable, including the potential for
allowances based on managements judgment. We have not historically experienced any significant losses. We do not currently require collateral for any of our trade accounts receivable.

Our future products will require approval from the U.S. Food and Drug Administration and foreign regulatory agencies before commercial
sales can commence. There can be no assurance that our products will receive any of these required approvals. The denial or delay of such approvals would have a material adverse impact on our business.

We have relied on a limited number of suppliers to produce ISS for clinical trials and a single contract manufacturer to produce our 1018
ISS for HEPLISAV. The loss of our current supplier could delay development or commercialization of our product candidates. To date, we have manufactured only small quantities of ISS and 1018 ISS ourselves for development purposes.

We are subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, new technological
innovations, clinical development risk, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of products, product liability, the volatility of our stock price and the need
to obtain additional financing.

Property and Equipment

Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. The assets held in our Berkeley facility have
estimated useful lives of three years for computer equipment and furniture, and five years for laboratory equipment. The assets in our Düsseldorf, Germany facility have estimated useful lives of three years for computer equipment and thirteen
years for furniture and laboratory equipment. Leasehold improvements in both facilities are amortized over the remaining life of the initial lease term or the estimated useful lives of the assets, whichever is shorter. Repair and maintenance costs
are charged to expense as incurred.

Impairment of Long-lived Assets

Long-lived assets to be held and used, including property and equipment and identified intangible assets, are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Factors we consider important that could indicate the need for an impairment review include the following:

a current expectation that, more likely than not, a long lived asset (asset group) will be sold or otherwise disposed of significantly before the end
of its previously estimated useful life; and



our market capitalization relative to net book value.

Recoverability is measured by comparison of the assets carrying amounts to the future net undiscounted cash flows resulting from the use of the asset and its eventual disposition. If these assets
are considered impaired, the impairment recognized is measured by the amount by which the carrying value of the assets exceed the projected discounted future net cash flows associated with the assets. For the years ended December 31, 2010, 2009
and 2008, we recognized no impairment charge as it relates to our long-lived assets.

Revenue Recognition

Our revenues are derived from collaborative and service agreements as well as grants. Collaborative agreements may include upfront license
payments, cost reimbursement for the performance of research and development, milestone payments, contract manufacturing services, and royalty fees. We recognize revenue when there is persuasive evidence that an arrangement exists, delivery has
occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Our revenue arrangements that contain multiple elements are evaluated under established accounting guidance. The different elements
of the revenue arrangement are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer and whether there is objective and reliable evidence of the fair
value of the undelivered items. The consideration we receive is allocated among the separate units based on their respective fair values, and the applicable revenue recognition criteria are applied to each of the separate units. For agreements which
do not meet the criteria of separate units of accounting, the total consideration received is grouped as one unit and the applicable revenue recognition methodology is applied to the single unit. Advance payments received in excess of amounts earned
are classified as deferred revenue until earned.

Revenue from non-refundable upfront license fees and other payments under
collaboration agreements where we have continuing performance obligations is deferred and recognized as performance occurs. Revenue is recognized on a ratable basis, unless we determine that another methodology is more appropriate, through the date
at which our performance obligations are completed. We recognize cost reimbursement revenue under collaborative agreements as the related research and development costs are incurred, as provided for under the terms of these agreements.

Revenue from milestones that are contingent upon the achievement of substantive at-risk performance criteria is recognized in full upon
achievement of those milestone events in accordance with the terms of the agreement and assuming all other revenue recognition criteria have been met. All revenue recognized to date under our collaborative agreements has been nonrefundable.

Revenues from the manufacturing and sale of vaccine and other materials are recognized upon meeting the criteria for
substantial performance and acceptance by the customer.

Revenue from royalty payments is contingent on future sales
activities by our licensees. As a result, we recognize royalty revenue when reported by our licensees and when collection is reasonably assured.

Revenue from government and private agency grants are recognized as the related research expenses are incurred and to the extent that funding is approved. Additionally, we recognize revenue based on the
facilities and administrative cost rate reimbursable per the terms of the grant awards.

Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial
costs, manufacturing and process development costs, research costs and other consulting services, and non-cash stock-based compensation. Research and development costs are expensed as incurred. For agreements with third parties for clinical trials,
manufacturing and process development, research and other consulting activities entered into prior to January 1, 2008, costs were expensed upon the earlier of when non-refundable amounts were due or as services were performed. Amounts due under
such arrangements may be either fixed fee or fee for service, and may include upfront payments, monthly payments, and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements entered
into after January 1, 2008 are capitalized and expensed as the related goods are delivered or services are performed.

Our accruals for clinical trials are based on estimates of the services received and efforts expended pursuant to contracts with clinical
trial centers and clinical research organizations. We contract with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation and
vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, the completion of portions of the
clinical trial or similar conditions. We may terminate these contracts upon written notice and we are generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances we may be further
responsible for termination fees and penalties.

Goodwill

Goodwill is recorded as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value, by applying the acquisition method of accounting.
The ongoing evaluation for impairment of goodwill requires significant management estimates and judgment. We determined that we have only one operating segment and there are no components of that operating segment that are deemed to be reporting
units. Since we are one reporting unit, we have allocated goodwill to that one reporting unit based on the relative fair value of the reporting unit. We evaluate goodwill for impairment on an annual basis and on an interim basis if events or changes
in circumstances between annual impairment tests indicate that the asset might be impaired.

Consolidation of Variable Interest Entities

Arrangements that are not controlled through voting or similar rights are accounted for as variable interest entities
(VIEs). An enterprise is required to consolidate a VIE if it is the primary beneficiary of the VIE. The enterprise that is deemed to absorb a majority of the expected losses or receive a majority of expected residual returns of the VIE
is considered the primary beneficiary.

We have concluded that under certain circumstances when we enter into agreements that
contain an option to purchase assets or equity securities from an entity, or enter into an arrangement with a financial partner for the formation of joint ventures which engage in research and development projects, a VIE may be created. For each VIE
created, we compute expected losses and residual returns based on the probability of future cash flows. If we are determined to be the primary beneficiary of the VIE, the assets, liabilities and operations of the VIE will be consolidated with our
financial statements. Prior to the acquisition of all of the outstanding equity of SDI pursuant to the Amended Purchase Option on December 30, 2009, our consolidated financial statements include the accounts of SDI, a VIE, of which we were the
primary beneficiary (refer to Note 8 below).

Determining the appropriate fair value model and calculating the fair value of stock-based awards at the grant date requires judgment and estimates. The fair value of each option is amortized on a
straight-line basis over the options vesting period and is estimated on the date of grant using the Black-Scholes option valuation model, which requires the input of highly subjective assumptions, including the expected life of the option and
expected stock price volatility. The expected life of options granted is estimated based on historical option exercise and employee termination data. Executive level and non-executive level employees were grouped and considered separately for
valuation purposes. In 2008, based on employee termination data we adjusted the expected life of the options for both groups of employees to four years, which remained consistent for fiscal years ended December 31, 2009 and 2010. Expected
volatility is based on historical volatility of our stock and comparable peer data over the life of the options granted to executive and non-executive level employees.

Income Taxes

We account for income taxes using the liability method under
ASC 740, Accounting for Income Taxes. Under this method, deferred tax assets and liabilities are determined based on temporary differences resulting from the different treatment of items for tax and financial reporting purposes. Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. Additionally, we must assess the likelihood that deferred tax assets will
be recovered as deductions from future taxable income. We have provided a full valuation allowance on our deferred tax assets because we believe it is more likely than not that our deferred tax assets will not be realized. We evaluate the
realizability of our deferred tax assets on a quarterly basis. Currently, there is no provision for income taxes as we have incurred losses to date.

We have no unrecognized tax benefits as of December 31, 2010, including no accrued amounts for interest and penalties. We do not anticipate that total unrecognized tax benefits will significantly
change prior to December 31, 2011. Our policy will be to recognize interest and penalties related to income taxes, if any, as a component of general and administrative expense. We are subject to income tax examinations for U.S. federal and
state income taxes from 1996 forward. We are subject to tax examinations in Singapore and Germany from 2003 and 2004 forward, respectively.

Recent Accounting Pronouncements

Accounting Standards Update 2010-17

In March 2010, the FASB reached
a consensus on Accounting Standards Update (ASU) No. 2010-17, Milestone Method of Revenue Recognition or ASU 2010-17. ASU 2010-17 provides guidance on applying the milestone method to milestone payments for achieving
specified performance measures when those payments are related to uncertain future events. Under the consensus, entities can make an accounting policy election to recognize arrangement consideration received for achieving specified performance
measures during the period in which the milestones are achieved, provided certain criteria are met. The scope of this issue is limited to transactions involving research or development. This new guidance is effective for fiscal years beginning on or
after June 15, 2010, and we will adopt it prospectively as of January 1, 2011 such that it will be applicable to revenue arrangements entered into or materially modified after that date. While we do not expect the adoption of this standard
to have a material impact on our financial position and results of operations, this standard may impact us in the event we complete future transactions or modify existing collaborative relationships.

Accounting Standards Update 2010-06

In January 2010, the FASB issued ASU No. 2010-06, Improving Disclosures about Fair Value Measurements or ASU 2010-06, which is included in the ASC Topic 820 (Fair Value Measurements and
Disclosures). ASU 2010-06 requires new disclosures on the amount and reason for transfers in and out of Level 1

and 2 fair value measurements. ASU 2010-06 also requires disclosure of activities including purchases, sales, issuances, and settlements within the Level 3 fair value measurements and clarifies
existing disclosure requirements on levels of disaggregation and disclosures about inputs and valuation techniques. We adopted ASU 2010-06 effective January 1, 2010. The adoption of ASU 2010-06 did not have a material impact on the consolidated
financial statements of the Company.

Accounting Standards Update 2009-13

In October 2009, the FASB issued ASU No. 2009-13,
Multiple-Deliverable Revenue Arrangements
or ASU No. 2009-13. ASU
No. 2009-13 amends existing revenue recognition accounting pronouncements and provides accounting principles and application guidance on whether multiple deliverables exist, how an arrangement should be separated and the consideration
allocated. This guidance eliminates the requirement to establish the fair value of undelivered products and services in order to treat deliverables in an arrangement as separate units of accounting and provides for separate revenue recognition based
upon managements estimate of the relative selling price for each deliverable in an arrangement. This new guidance is effective for fiscal years beginning on or after June 15, 2010, and we will adopt it prospectively as of January 1,
2011 such that it will be applicable to revenue arrangements entered into or materially modified on or after that date. While we do not expect the adoption of this standard to have a material impact on our financial position and results of
operations, this standard may impact us in the event we complete future transactions or modify existing collaborative relationships.

3. Fair Value Measurements

ASC 820 defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined
under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on
the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of
inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted
prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and



Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or
liabilities.

The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable securities) and
liabilities measured at fair value on a recurring basis as of December 31, 2010 and 2009 (in thousands):

Level 1

Level 2

Level 3

Total

December 31, 2010

Assets:

Money market funds

$

18,980

$



$



$

18,980

U.S. government agency securities



49,039



49,039

Corporate debt securities



1,764



1,764

Total assets

$

18,980

$

50,803

$



$

69,783

Liabilities:

Long-term contingent consideration liability to Holdings

$



$



$

843

$

843

Total liabilities

$



$



$

843

$

843

Level 1

Level 2

Level 3

Total

December 31, 2009

Assets:

Money market funds

$

33,788

$



$



$

33,788

Total assets

$

33,788

$



$



$

33,788

Liabilities:

Warrant liability to Holdings

$



$



$

2,567

$

2,567

Long-term contingent consideration liability to Holdings





3,040

3,040

Total liabilities

$



$



$

5,607

$

5,607

Assets

Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments are readily available and can be independently validated as of the
measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.

Marketable securities are primarily comprised of U.S. Government sponsored and corporate debt securities which are measured at fair value
using Level 2 inputs. The company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the company uses market pricing and other observable
market inputs for similar securities obtained from various third party data providers. These inputs represent quoted prices for similar assets in active markets or these inputs have been derived from observable market data. This approach results in
the classification of these securities as Level 2 of the fair value hierarchy.

When determining if there are any
other-than-temporary impairments on its investments, we evaluate: (i) whether the investment has been in a continuous realized loss position for over 12 months, (ii) the duration to maturity of our investments, (iii) our
intention to hold the investments to maturity and if it is not more likely than not that the Company will be required to sell the investment before recovery of the amortized cost bases, (iv) the credit rating of each investment, and
(v) the type of investments made. Through December 31, 2010, we have not recognized any other-than-temporary losses on our investments.

Liabilities

In connection with the exercise of the Companys purchase
of all of the outstanding equity of SDI on December 30, 2009, we issued warrants to Holdings that were subject to certain anti-dilution protection in the

event that we issued other equity securities within six months from December 30, 2009. Due to this adjustment provision, the warrants did not meet the criteria set forth in ASC 815 to be
considered indexed to the Companys own stock and therefore were recorded as a liability at fair value, which was estimated at the issuance date using the Black-Scholes Model. This fair value measurement was based on significant inputs not
observed in the market and thus represents a Level 3 measurement. Level 3 instruments are valued based on unobservable inputs that are supported by little or no market activity and reflect our assumptions in measuring fair value. In connection with
an equity offering completed in April 2010 prior to the expiration of the anti-dilution provision, Holdings received warrants to purchase 7,038,210 shares of common stock (April 2010 Warrants). The warrants issued on December 30,
2009 were cancelled upon the issuance of the April 2010 Warrants.

The incremental fair value of the April 2010 Warrants was
remeasured at June 30, 2010 and resulted in an increase of $9.5 million to the warrant liability, which was reported as a other expense in the consolidated statement of operations. Following the expiration of Symphonys anti-dilution
protection on June 30, 2010, the value of the April 2010 Warrants of $12.1 million was reclassified into stockholders equity in the consolidated balance sheet.

The following table represents a reconciliation of the change in the fair value measurement of the warrant liability for the fiscal year ended December 31, 2010 (in thousands):

Warrant Liability to Holdings

Amount

Acquisition date fair value measurement at December 30, 2009

$

2,567

Adjustment to fair value measurement

9,462

Reclassification of warrant liability into equity

(12,029

)

Balance as of December 31, 2010

$



The original warrants and the April 2010 Warrants were valued and their related assumptions under the
Black-Scholes option valuation model are as follows (in thousands, except for Black-Scholes assumptions):

Black-Scholes Assumptions

Warrant Liability Measurement Date:

Risk-Free
Interest Rate

Expected
Life (in
years)

Volatility

Exercise
Price per
Share

Assigned Value
using Black-
Scholes

December 30, 2009

2.6

%

5.0

1.5

$

1.94

$

2,567

March 31, 2010

2.6

%

4.8

1.5

$

1.94

$

2,315

April 16, 2010

2.5

%

4.7

1.5

$

1.94

$

2,579

June 30, 2010

1.8

%

4.8

1.5

$

1.50

$

12,029

We are obligated to
make future contingent cash payments to the former Holdings shareholders related to certain payments received by us, if any, from future partnering agreements pertaining to our hepatitis C and cancer therapy programs (see Note 8). We estimated the
fair value of this contingent liability using a discounted cash flow model. The discounted cash flow model was derived from managements assumptions regarding the timing, amounts, and probability of potential upfront and milestone payments for
the development and/or commercialization of the hepatitis C program based on transactions for similar stage programs by other companies. These cash flows were discounted at 16% and 18% rates for the fiscal years ended December 31, 2010 and
2009, respectively.

Changes in the fair value of the contingent consideration liability are recognized in Other income
(expense) in the statement of operations in the period of the change. Certain events including, but not limited to, the timing and terms of any strategic partnership agreement of the hepatitis C therapy program could have a material impact on the
fair value of the contingent consideration liability, and as a result, the Companys results of operations and financial position. During the fiscal year ended December 31, 2010, we reduced the assumed probability of our receipt of upfront
and milestone payments from a potential partnership and extended the timing of when these

expected receipts would occur. In addition, based on our assumptions regarding the Companys beta and risk free interest rate used in the discounted cash flow model and the timing of the
expected cash receipts, the change in fair value of the contingent consideration liability resulted in other income of $2.2 million for the fiscal year ended December 31, 2010. This fair value measurement was based on significant inputs not
observed in the market and thus represents a Level 3 measurement. Level 3 instruments are valued based on unobservable inputs that are supported by little or no market activity and reflect our assumptions in measuring fair value.

The following table represents a reconciliation of the change in the fair value measurement of the contingent liability for the fiscal
year ended December 31, 2010 (in thousands):

Long-term Contingent Liability to Holdings:

Amount

Acquisition date fair value measurement at December 30, 2009

$

3,040

Adjustment to fair value measurement

(2,197

)

Balance as of December 31, 2010

$

843

4. Available-for-Sale Securities

The following is a summary of available-for-sale securities included in cash and cash equivalents and marketable securities as of
December 31, 2010 and 2009 (in thousands):

Amortized
Cost

Unrealized
Gains

Unrealized
Losses

Estimated
Fair Value

December 31, 2010:

Certificates of deposit and money market funds

$

19,797

$



$



$

19,797

U.S. Government agency securities

49,056



(17

)

49,039

Corporate debt securities

1,764





1,764

Total

$

70,617

$



$

(17

)

$

70,600

December 31, 2009:

Certificates of deposit and money market funds

$

34,634

$



$



$

34,634

There were no
realized gains or losses from the sale of marketable securities in the years ended December 31, 2010, 2009 and 2008. As of December 31, 2010, all of our investments have a stated maturity date that is within one year of the current balance
sheet date. All of our investments are classified as short-term and available-for-sale, as we may not hold our investments until maturity.

5. Property and Equipment

Property and equipment as of December 31, 2010 and 2009 consist of the following (in thousands):

December 31,

2010

2009

Laboratory equipment

$

14,173

$

14,937

Computer equipment

1,341

1,331

Furniture and fixtures

1,518

1,581

Leasehold improvements

3,872

3,734

20,904

21,583

Less accumulated depreciation and amortization

(14,500

)

(13,586

)

Total

$

6,404

$

7,997

Depreciation and amortization expense on property and equipment was $1.4 million, $1.9 million and
$1.9 million for the years ended December 31, 2010, 2009 and 2008, respectively.

Intangible assets consist primarily of manufacturing process and customer relationships. The manufacturing process derives from the
methods for making proteins in Hansenula yeast, which is a process we use to make a key component in the production of hepatitis B vaccine. The customer relationships derive from Rheins ability to sell existing, in-process and future products
to its existing customers. Purchased intangible assets other than goodwill are amortized on a straight-line basis over their respective useful lives. The following tables present details of the purchased intangible assets at December 31, 2010
and December 31, 2009 (in thousands):

December 31, 2010

December 31, 2009

Estimated Useful
Life
(In
years)

Gross

Accumulated
Amortization

Net

Gross

Accumulated
Amortization

Net

Intangible Assets:

Manufacturing process

5

$

3,670

$

(3,446

)

$

224

$

3,670

$

(2,712

)

$

958

Customer relationships

5

1,230

(1,155

)

75

1,230

(909

)

321

Total

$

4,900

$

(4,601

)

$

299

$

4,900

$

(3,621

)

$

1,279

The estimated future amortization expense of purchased intangible assets is $0.3 million through
2011.

7. Current Accrued Liabilities

Current accrued liabilities as of December 31, 2010 and 2009 consist of the following (in thousands):

December 31,

2010

2009

Payroll and related expenses

$

2,485

$

2,521

Legal expenses

596

1,140

Third party research and development expense

6,130

2,155

Deferred Rent

784

860

Other accrued liabilities

948

831

Total

$

10,943

$

7,507

8. Symphony Dynamo, Inc.

On April 18, 2006, we, Symphony Capital Partners, L.P. and certain of its affiliates (together, Symphony) and Holdings
entered into a transaction involving a series of related agreements providing for the advancement of certain of our immunostimulatory sequences-based programs for cancer, hepatitis B and hepatitis C therapy (collectively, the Programs).
Pursuant to these agreements, Symphony formed SDI and invested $50 million to fund the Programs, and we licensed to Holdings our intellectual property rights related to the Programs, which were assigned to SDI. As a result of these agreements,
Symphony owned 100% of the equity of Holdings, which owned 100% of the equity of SDI.

In connection with the transaction
described above, Holdings granted to us an exclusive purchase option that gave us the right, but not the obligation, to acquire the outstanding equity securities of SDI, which would result in our reacquisition of the intellectual property rights
that we licensed to Holdings (the Original Purchase Option). In exchange for the Original Purchase Option, we granted Holdings five-year warrants to purchase up to 2,000,000 shares of our common stock at an exercise price of $7.32 per
share pursuant to a warrant purchase agreement (the Original Warrants), and granted certain registration rights to Holdings pursuant to a registration rights agreement. We also received an exclusive option to purchase either the
hepatitis B or hepatitis C therapy program (the Program Option) during the first year of the arrangement. In April 2007, we exercised the Program Option for the hepatitis B program. We remained primarily responsible for
the development of the cancer and hepatitis C therapy programs in accordance with a development plan and related development budgets that we agreed to with Holdings.

A variable interest entity, or VIE, is (i) an entity that has equity that is
insufficient to permit the entity to finance its activities without additional subordinated financial support, or (ii) an entity that has equity investors that cannot make significant decisions about the entitys operations or that do not
absorb their proportionate share of the expected losses or do not receive the expected residual returns of the entity. A VIE is required to be consolidated by the party that is deemed to be the primary beneficiary, which is the party that has
exposure to a majority of the potential variability in the VIEs outcomes. Significant management judgment is required in the determination of an entity being considered a VIE.

Parties are deemed to be de facto agents if they cannot sell, transfer, or encumber their interests without the prior approval of an
enterprise. Symphony is considered to be a de facto agent of the Company pursuant to this provision, and because we and Symphony as a related party group absorb a majority of SDIs variability, we evaluated whether we are most closely
associated with SDI. We concluded that we were most closely associated with SDI and should consolidate SDI because (1) we originally developed the technology that was assigned to SDI, (2) we continued to oversee and monitor the Development
Programs, (3) our employees continued to perform substantially all of the development work, (4) we significantly influenced the design of the responsibilities and management structure of SDI, (5) SDIs operations were
substantially similar to our activities, and (6) through the Purchase Option, we had the ability to participate in the benefits of a successful development effort.

Prior to the acquisition of all of the outstanding equity of SDI pursuant to the Amended Purchase Option on December 30, 2009, as described below, we consolidated the financial position and results
of operations of SDI. Net losses incurred by SDI and charged to the noncontrolling interest were $4.2 million and $5.7 million for the fiscal years ended December 31, 2009 and 2008, respectively. We did not consolidate Holdings because we
believed our variable interest, the Purchase Option, was on the stock of SDI. We believed SDI was a VIE because we had the Purchase Option to acquire its outstanding voting stock at prices that were fixed upon entry into the arrangement, with the
specific price based upon the date the option is exercised. The fixed nature of the Purchase Option price limits Symphonys returns, as the investor in SDI.

Symphony was required to absorb the development risk for its equity investment in SDI. Symphonys equity investment in SDI was classified as a noncontrolling interest in the consolidated balance
sheet. The noncontrolling interest held by Symphony was reduced by the $5.6 million fair value of the warrants it received and $2.6 million of fees we immediately paid to Symphony upon the transactions closing because the total consideration
provided by us to Symphony effectively reduces Symphonys at-risk equity investment in SDI. While we performed the research and development on behalf of SDI, our development risk was limited to the consideration we provided to Symphony (the
warrants and fees). We exercised the Program Option in April 2007, which resulted in the recognition of a $15.0 million liability to Symphony. The noncontrolling interest was further reduced for this obligation as it would have been paid to Symphony
at the expiration of the SDI collaboration in 2011 if we did not exercise the Purchase Option, or would be included as part of the applicable purchase price upon exercise of the Purchase Option.

In December 2007, the FASB issued new guidance that required: (i) noncontrolling interests in subsidiaries be reported as a
component of stockholders equity in the consolidated balance sheet, (ii) noncontrolling interests continue to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance, (iii) that
earnings or losses attributed to the noncontrolling interests be reported as part of consolidated earnings and not as a separate component of income or expense, and (iv) disclosure of the attribution of consolidated earnings to the controlling
and noncontrolling interests on the face of the consolidated statement of operations. On January 1, 2009, we adopted these provisions. Had the previous requirements been applied, the consolidated net loss attributable to our common stockholders
would have increased by $1.9 million and the loss per share attributable to our common stockholders would have increased by $0.05, during the year ended December 31, 2009.

In November 2009, we entered into an agreement with Holdings to modify the provisions of and to exercise the Original Purchase
Option. We completed the acquisition of all of the outstanding equity of SDI on

December 30, 2009. In exchange for all of the outstanding equity of SDI, we issued to Symphony and certain of its co-investors: (i) 13,000,000 shares of common stock (the
Shares); (ii) 5-year warrants to purchase 2,000,000 shares of common stock with an exercise price of $1.94 per share (the Warrants); and (iii) a note in the principal amount of $15 million, due December 31,
2012, payable in cash, our common stock or a combination thereof at our discretion, which obligation was previously payable solely in cash on April 18, 2011. In addition, we agreed to contingent cash payments from us equal to 50% of the
first $50 million from any upfront, pre-commercialization milestone or similar payments received by us from any agreement with any third party with respect to the development and/or commercialization of the cancer and hepatitis C therapies
originally licensed to SDI. The Original Warrants held by Symphony were cancelled as part of this transaction.

We recorded
the acquisition of all of the outstanding equity of SDI pursuant to the Amended Purchase Option as a return of equity to the noncontrolling interest. The acquisition was accounted for as a capital transaction that did not affect our consolidated net
loss. However, because the acquisition was accounted for as a capital transaction, the consideration paid in excess of the carrying value of the noncontrolling interest in SDI is treated as a deemed dividend for purposes of reporting net loss and
earnings per share, increasing net loss and net loss per share attributable to us for the year ended December 31, 2009. We ceased to charge net losses incurred by SDI against the noncontrolling interest upon our acquisition of SDI on
December 30, 2009.

The fair value of our common stock issued to the Symphony investors was based on the closing sales
price of our common stock on the NASDAQ Capital Market on December 30, 2009, the date the transaction was completed. The estimated fair values of the warrants transferred were calculated using the Black-Scholes valuation model.

We estimated the fair value of the non-interest bearing note payable to Holdings using a net present value model using a discount rate of
17%. Imputed interest will be recorded as interest expense over the term of the loan. The principal amount of $15 million is due on December 31, 2012 and is payable in cash, our common stock or a combination thereof at our discretion. If we
elect to pay the note in shares of our common stock, the number of shares issued will be determined by our stock price at the date of payment.

We estimated the fair value of the contingent consideration liability for potential future payments using a discounted cash flow model. The discounted cash flow model was derived from managements
assumptions regarding the timing, amounts, and probability of potential upfront and milestone payments for the development and/or commercialization of the hepatitis C program based on transactions for similar stage programs by other companies. These
cash flows were discounted at a 16% rate.

Changes in the fair value of the acquisition-related contingent consideration
liability subsequent to the December 30, 2009 acquisition date are recognized in other income and expense on our consolidated statement of operations in the period of the change. Certain events including, but not limited to the timing and terms
of a strategic partnership, and the commercial success of the programs could have a material impact on the fair value of the contingent liability, and as a result, our results of operations.

The Shares and Warrants were subject to certain anti-dilution protection in the event that we issued other equity securities within six
months from December 30, 2009. Due to this adjustment provision, the Warrants did not meet the criteria set forth in ASC 815 to be considered indexed to the Companys own stock and therefore were recorded as a liability at fair value,
which was estimated at the issuance date using the Black-Scholes Model. As a result of an equity offering completed in April 2010 prior to the expiration of the anti-dilution provision, Symphony received an additional 1,076,420 shares of common
stock (April 2010 Shares) and warrants to purchase 7,038,210 shares of common stock (April 2010 Warrants) having the same terms as the warrants sold in the offering, which have an exercise price of $1.50 per share and a term
of five years. The Warrants issued on December 30, 2009 were cancelled upon the issuance of the April 2010 Warrants.

The
fair value of the April 2010 Shares and incremental fair value of the April 2010 Warrants provided to Symphony, as measured upon issuance and remeasured at June 30, 2010, resulted in non-operating expense of

$11.1 million in the second quarter of 2010. This also resulted in an increase of $9.5 million to the warrant liability and an increase of $1.6 million to additional paid in capital as of
June 30, 2010. Following the expiration date of Symphonys anti-dilution protection on July 1, 2010, the value of the April 2010 Warrants of $12.0 million was reclassified in stockholders equity in the consolidated balance
sheet.

9. Financing Agreements

On November 2, 2010, we completed an underwritten public offering of 26,450,000 shares of our common stock including 3,450,000 shares sold pursuant to the full exercise of an overallotment option
previously granted to the underwriters at a price to the public of $1.70 per share. The net proceeds to us from this offering were $42.0 million, after deducting underwriting discounts and commissions and other offering expenses payable by us.

On September 20, 2010, we entered into the Purchase Agreement with Aspire Capital, which provides that, upon the terms
and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of shares of Dynavax common stock over the 25-month term of the Purchase Agreement. Under the Purchase
Agreement, we agreed to pay Aspire Capital a commitment fee equal to 4% of $30 million in consideration for Aspire Capitals obligation to purchase up to $30 million of Dynavax common stock. We paid this commitment fee of $1.2 million by
issuance of 600,000 shares of our common stock which were recorded as a cost of raising capital and netted against the gross proceeds. Upon execution of the Purchase Agreement, we sold 1,000,000 shares of common stock to Aspire Capital at a purchase
price of $2.00 per share, for an aggregate purchase price of $2.0 million.

Pursuant to the Purchase Agreement, on any
business day on which the closing sale price of our common stock exceeds $1.00, over the 25-month term of the Purchase Agreement, we have the right, in our sole discretion, to present Aspire Capital with a purchase notice directing Aspire Capital to
purchase up to 150,000 Purchase Shares per business day (defined in the Purchase Agreement as any day on which the principal market is open for trading including any day on which the principal market is open for trading for a period of time less
than the customary time). We and Aspire Capital may mutually agree to increase the number of shares that may be sold per business day to as much as an additional 1,000,000 Purchase Shares per business day. The purchase price per Purchase Share is
the lower of (i) the lowest sale price for the common stock on the date of sale or (ii) the arithmetic average of the three lowest closing sale prices for the common stock during the 12 consecutive business days ending on the business day
immediately preceding the purchase date of those securities. During the year ended December 31, 2010, we sold through Aspire Capital an aggregate of 2,350,000 shares of common stock for net proceeds of $3.2 million after deducting offering
expenses. As of December 31, 2010, we could offer and sell from time to time through Aspire Capital up to an additional $26.7 million in aggregate offering proceeds of our common stock under the Purchase Agreement.

On April 16, 2010, we completed an underwritten public offering resulting in net proceeds of $41.1 million, after deducting the
underwriting discount and offering expenses of approximately $3.0 million, from the sale of 30,293,000 units at a per unit price of $1.4525. Each unit consisted of one share of common stock and one warrant to purchase 0.5 of a share of common stock.
Each warrant has an exercise price of $1.50 per share, and is exercisable for a period of five years from the date of issuance. From this offering, warrants to purchase an aggregate of 15,145,669 shares of our common stock were outstanding as of
December 31, 2010.

On August 17, 2009, we entered into an equity distribution agreement with Wedbush Morgan
Securities, Inc. (Wedbush) pursuant to which we could offer and sell shares of our common stock having an aggregate offering price of up to $15 million from time to time through Wedbush as our sales agent or to Wedbush as a principal.
During the fiscal year ended December 31, 2009, we sold 1,281,100 shares of common stock under the agreement with Wedbush as our sales agent for aggregate net proceeds of $2.3 million after deducting commissions paid to Wedbush and offering
expenses. On September 14, 2010, the Company terminated the agreement with Wedbush. Prior to the termination of the agreement on September 14, 2010, during the year ended December 31, 2010 we sold 900,860 shares of common stock under
the agreement with Wedbush as our sales agent for net proceeds of $1.2 million.

On August 26, 2008, we and Deerfield Management, a healthcare investment fund, and its
affiliates (Deerfield) entered into a Settlement Agreement and Mutual General Release (the Settlement Agreement) under which the parties agreed to terminate the Loan Agreement dated July 18, 2007 (the Loan
Agreement) and also to provide for an amendment of the warrants previously issued to Deerfield pursuant to the Loan Agreement. The Settlement Agreement terminated any further obligations under the Loan Agreement.

Under the Loan Agreement, Deerfield agreed to advance to us loans that could be drawn down over a three-year period in the aggregate
principal amount of up to $30 million, subject to achievement of specific milestones in relation to the development of certain products in our allergy franchise. Repayment of a portion of the loans to Deerfield was contingent upon the positive
outcome of studies related to TOLAMBA, our product candidate for the treatment of ragweed allergy. If the TOLAMBA program was discontinued, we would have had no obligation to repay Deerfield up to $9 million of the funds earmarked for that
program; any other remaining outstanding principal was slated to be due in July 2010. Deerfield received an annual 5.9% cash commitment fee as well as milestone-driven payments in the form of warrants issued or issuable at an exercise premium of 20%
over the volume weighted average price in the 15-day period prior to achievement of certain milestones.

Under the Loan
Agreement, through August 26, 2008 (the date of termination), we had received $7.5 million in cash from Deerfield, which was recorded as a long-term liability in our consolidated balance sheet. Additionally, we paid and recognized as interest
expense $1.7 million of commitment fees and we issued to Deerfield warrants to purchase up to 3,550,000 shares of our common stock. The warrants were valued on the issuance date using the Black-Scholes valuation model. The original warrants issued
and their related assumptions under the Black-Scholes option valuation model are as follows (in thousands, except for Black-Scholes assumptions):

Black-Scholes Assumptions

Warrant Issuance Date

Shares
Issued

Risk-Free
Interest Rate

Expected
Life (in
years)

Volatility

Exercise
Price per
Share

Assigned Value
using Black-
Scholes

July 18, 2007

1,250

4.9

%

5.5

0.7

$

5.13

$

3,350

October 18, 2007

1,300

4.2

%

5.5

0.7

$

5.75

3,700

December 27, 2007

1,000

3.6

%

5.5

0.7

$

5.65

2,746

Total

3,550

$

9,796

At the date of each issuance, the warrant valuation was recorded as a deferred transaction cost in other
assets and an increase in additional paid in capital. The deferred transaction cost was amortized on a straight-line basis and recognized as interest expense through the termination of the Loan Agreement. We amortized $9.0 million of deferred
transaction cost into in interest expense in the year ended December 31, 2008.

Under the Settlement Agreement, $5.0
million of funds received for the TOLAMBA program were forgiven, resulting in loan forgiveness in the statement of operations for the year ended December 31, 2008. All commitment fees paid to date, which totaled $1.7 million, were applied to
the loan, resulting in a reduction in interest expense for the year ended December 31, 2008. We paid the remaining loan balance of $0.8 million in cash to Deerfield. In addition, the warrants previously issued to Deerfield were
amended as follows:

Pursuant to the Settlement Agreement, the warrants to purchase an aggregate of 700,000 shares of our common stock issued on December 27, 2007
were amended on August 26, 2008 to provide for a termination date of February 26, 2014 at the existing exercise price of $5.65 and were further amended on August 26, 2009 to provide for a new exercise price of $1.68,
which is equal to the volume weighted average price over the 15 trading days prior to August 26, 2009.

The
amendments to the warrants resulted in a re-measurement of the fair value based on the amended terms and current period assumptions and were accounted for as modifications to equity awards under the provisions of Topic 718,
Compensation-Stock
Compensation
. We recorded interest expense and an increase of additional paid in capital of $0.1 million and $0.9 million for the years ended December 31, 2009 and 2008, respectively, due to these modifications. There were no amendments or
additional contractual obligations during the year ended December 31, 2010. Additionally, there were no exercises of warrants during the years ended December 31, 2010 and 2009.

10. Commitments and Contingencies

We lease our
facilities in Berkeley, California (the Berkeley Lease), and Düsseldorf, Germany (the Düsseldorf Lease), under operating leases that expire in September 2017 and March 2023, respectively. In October 2010, we amended
our Berkeley Lease to reduce our leased premises and extended the term of the lease through September 30, 2017. Commencing on the reduction effective date, which is no later than April 1, 2011, the monthly base rent for the Berkeley
facility will be reduced proportionately by the reduction in square footage and is subject to scheduled escalation on an annual basis thereafter. The total cash payments over the life of the lease were divided by the total number of months in the
lease period and the average rent is charged to expense each month during the lease period. Total net rent expense related to our operating leases for the years ended December 31, 2010, 2009 and 2008, was $2.6 million, $2.5 million and $2.5
million, respectively. Deferred rent was $0.8 million and $0.9 million as of December 31, 2010 and 2009, respectively.

We have entered into a sublease agreement under the Berkeley Lease for a certain portion of the leased space with the remaining scheduled
payments to us totaling $10,600 until February 2011. The sublease rental income is offset against rent expense.

Future
minimum payments under the non-cancelable portion of our operating leases at December 31, 2010, excluding payments from the sublease agreement, are as follows (in thousands):

Year ending December 31,

2011

$

2,023

2012

1,860

2013

1,882

2014

1,845

Thereafter

8,382

Total

$

15,992

During the fourth quarter of 2004, we established a letter of credit with Silicon Valley Bank as security
for our Berkeley Lease in the amount of $0.4 million. The letter of credit remained outstanding as of December 31, 2010 and is collateralized by a certificate of deposit which has been included in restricted cash in the consolidated balance
sheets as of December 31, 2010 and 2009. Under the terms of the Berkeley Lease, if the total amount of our cash, cash equivalents and marketable securities falls below $20.0 million for a period of more than 30 consecutive days during the lease
term, the amount of the required security deposit will increase to $1.1 million, until such time as our projected cash and cash equivalents will exceed $20.0 million for the remainder of the lease term, or until our actual cash and cash equivalents
remains above $20.0 million for a period of 12 consecutive months.

We established a letter of credit with Deutsche Bank as security for our Düsseldorf
Lease in the amount of $0.3 million. The letter of credit remained outstanding as of December 31, 2010 and is collateralized by a certificate of deposit which has been included in restricted cash in the consolidated balance sheets as of
December 31, 2010 and 2009.

In addition to the non-cancelable commitments included above, we have entered into
contractual arrangements that obligate us to make payments to the contractual counterparties upon the occurrence of future events. In the normal course of operations, we have entered into license and other agreements and intend to continue to seek
additional rights relating to compounds or technologies in connection with our discovery, manufacturing and development programs. Under the terms of the agreements, we may be required to pay future up-front fees, milestones and royalties on net
sales of products originating from the licensed technologies. We consider these potential obligations to be contingent and have summarized all significant arrangements below.

We rely on research institutions, contract research organizations, clinical investigators and clinical material manufacturers. As of December 31, 2010, under the terms of our agreements, we are
obligated to make future payments as services are provided of approximately $10.6 million through 2013. These agreements are terminable by us upon written notice. We are generally only liable for actual effort expended by the organizations at any
point in time during the contract, subject to certain termination fees and penalties.

Under the terms of our exclusive
license agreements with the Regents of the University of California, as amended, for certain technology and related patent rights and materials, we pay annual license or maintenance fees and will be required to pay milestones and royalties on net
sales of products originating from the licensed technologies.

11. Collaborative Research, Development, and License
Agreements

GlaxoSmithKline

In December 2008, we entered into a worldwide strategic alliance with GSK to discover, develop, and commercialize toll-like receptor (TLR) inhibitors for diseases such as lupus, psoriasis, and
rheumatoid arthritis. We received an initial payment of $10 million and agreed to conduct research and early clinical development in up to four programs and are eligible to receive future potential development and commercialization milestone
payments. GSK can exercise its exclusive option to license each program upon achievement of proof-of-concept or earlier upon certain circumstances. After exercising its option, GSK would carry out further development and commercialization of these
products. We are eligible to receive tiered, up to double-digit royalties on sales and have retained an option to co-develop and co-promote one product. Revenue from the initial payment is deferred and is being recognized over the expected period of
performance which is estimated to be seven years. For the years ended December 31, 2010, 2009 and 2008, we recognized revenue of $1.4 million, $1.4 million and $60 thousand, respectively, related to the initial payment.

AstraZeneca

In September 2006, we entered into a three-year research collaboration and license agreement with AstraZeneca for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma
and chronic obstructive pulmonary disease. Such agreement was extended through July 2010. The collaboration is using our proprietary second-generation TLR9 agonist immunostimulatory sequences or ISS. AstraZeneca has the right to sublicense its
rights upon our prior consent. We have the option to co-promote in the United States products arising from the collaboration, if any. We received an upfront payment of $10 million, and are eligible to receive research funding, preclinical milestone
payments, and potential future development milestones payments. Upon commercialization, we are also eligible to receive royalties based on product sales, if any.

In September 2008, we received a $4.5 million milestone payment from AstraZeneca for the nomination of a candidate drug. Revenue from milestones received during the development plan is deferred and
recognized

ratably over our estimated performance period under the collaboration agreement. Revenue from the upfront payment had been deferred until certain contractual obligations were amended in September
2010. In September 2010, we amended our research collaboration and license agreement with AstraZeneca to amend certain indemnification obligations which allowed for the $10 million upfront payment to be fully recognized as collaboration revenue in
the third quarter of 2010. Revenue from the milestone payment received was deferred and recognized ratably over the estimated performance period of the collaboration agreement. For the years ended